US Pat. No. 9,405,886

METHOD FOR DETERMINING CARDIOVASCULAR INFORMATION

THE BOARD OF TRUSTEES OF ...

1. A method for determining cardiovascular information for a patient, the method comprising:
receiving, using at least one computer system, patient-specific image data representing a first portion of a cardiovascular
structure generated using non-invasive imaging techniques, wherein the first portion includes at least one coronary artery
emanating from the patient's aorta;

receiving, using at least one computer system, patient-specific image data representing a second portion of the cardiovascular
structure generated using non-invasive imaging techniques, wherein the second portion includes at least one coronary artery
located downstream from the first portion;

creating, using at least one computer system, a three-spatial-dimension model of the first portion of the cardiovascular structure
using the patient-specific image data, wherein the three-spatial-dimension model is associated with a first set of fluid dynamics
equations representing the flow of fluid through the cardiovascular structure and comprising one or more parameters for blood
flow rate, coronary blood pressure, and/or vessel wall displacement;

receiving, using at least one computer system, vessel morphology data generated using non-invasive imaging techniques;
receiving, using at least one computer system, at least one non-patient-specific resistance parameter value;
creating, using at least one computer system, a lumped-parameter coronary vascular model of the second portion of the cardiovascular
structure using the vessel morphology data and the at least one non-patient-specific resistance parameter value, wherein the
lumped-parameter coronary vascular model is associated with a second set of fluid dynamics equations comprising one or more
parameters including at least one flow resistance parameter, and wherein the lumped-parameter coronary vascular model has
less than three spatial dimensions;

generating, using at least one computer system, a modified model representing the first and second portions of the cardiovascular
structure by coupling the three-spatial-dimension model of the first portion of the cardiovascular structure with the lumped-parameter
coronary vascular model of the second portion of the cardiovascular structure, wherein the first set and second set of fluid
dynamics equations associated with the three-spatial-dimension model and the lumped-parameter model are mathematically coupled;

calculating, using at least one computer system, one or more blood flow characteristics including blood flow rate, coronary
blood pressure, and/or vessel wall displacement in the first portion of the cardiovascular structure using the modified model
by simultaneously solving the mathematically coupled first set and second set of fluid dynamics equations associated with
the modified model; and

displaying, using at least one computer system, a visual representation based on the blood flow rate, coronary blood pressure,
and/or vessel wall displacement.

US Pat. No. 9,380,695

TRAVELING WAVE LINEAR ACCELERATOR WITH RF POWER FLOW OUTSIDE OF ACCELERATING CAVITIES

The Board of Trustees of ...

1. A traveling wave accelerator structure comprising: a symmetric RF feed; an input matching cell coupled to the symmetric
RF feed; a sequence of regular accelerating cavities coupled to the input matching cell at an input beam pipe end of the sequence;
a waveguide parallel to the sequence of regular accelerating cavities, an output matching cell coupled to the sequence of
regular accelerating cavities at an output beam pipe end of the sequence of regular accelerating cavities; and output waveguide
circuit or RF loads coupled to the output matching cell, wherein the waveguide is coupled at an input end to the symmetric
RF feed, coupled at an output end to the output waveguide circuit or RF loads, coupled to the input matching cell, coupled
to the output matching cell, and coupled to each of the cavities in the sequence of regular accelerating cavities, wherein
each of the regular accelerating cavities has a nose cone that cuts-off field propagating into the beam pipe such that all
power flows in a traveling wave along the structure in the waveguide.

US Pat. No. 9,356,779

SYSTEMS AND METHODS FOR IDENTITY-BASED ENCRYPTION AND RELATED CRYPTOGRAPHIC TECHNIQUES

The Board of Trustees of ...

1. A method, comprising:
with computing equipment, encrypting data using a public key that is formed using an identity, wherein encrypting the data
comprises encrypting the data using cryptographic system parameters and a bilinear map, wherein the cryptographic system parameters
include an element P of an algebraic group and a computed value sP, wherein s represents a secret master key, and wherein
encrypting the data using the cryptographic system parameters and the bilinear map comprises:

with the computing equipment, obtaining the cryptographic system parameters P and sP;
with the computing equipment, selecting a random secret r; and
with the computing equipment, encrypting the data using r, sP, the public key that is formed using the identity, and the bilinear
map.

US Pat. No. 9,204,309

SPECTRUM SHARING USING POWER SPLIT BETWEEN PRIMARY AND SECONDARY TRANSMITTERS

The Board of Trustees of ...

1. A method for wireless spectrum sharing, the method comprising:
broadcasting a primary signal from a primary transmitter using a primary wireless spectrum assigned to a primary communication
system;

transmitting a secondary signal from a secondary transmitter to a secondary receiver using the primary wireless spectrum assigned
to the primary communication system, wherein the secondary transmitter and the secondary receiver belong to a secondary communication
system to which no wireless spectrum is assigned, or to which a secondary wireless spectrum is assigned, wherein the secondary
wireless spectrum is distinct from the primary wireless spectrum;

wherein transmitting the secondary signal from the secondary transmitter comprises transmitting with a total power P split
between power ?P used by the secondary transmitter to transmit the primary signal, whereby the primary signal broadcasted
by the primary transmitter is amplified, and power (1??)P used by the secondary transmitter to transmit the secondary signal
to the secondary receiver;

wherein ? is computed by the secondary transmitter to protect the primary signal from quality of service degradation caused
by the secondary signal by selecting ? such that the power (1??)P of the secondary signal ensures that an SINR of the primary
signal received by a hypothetical primary receiver located near the secondary transmitter exceeds a predetermined SINR threshold.

US Pat. No. 9,494,777

MULTI-FOCI LASER SCANNING MICROSCOPE AND USE OF SAME FOR ANALYZING SAMPLES

The Board of Trustees of ...

1. A laser scanning microscope comprising:
a laser generator that generates a plurality of time-multiplexed N by M beams in an illumination cycle having a plurality
of phases, wherein N and M are each at least 2;

a beam scanner that scans the plurality of beams across a sample to be observed;
an objective that focuses the plurality of beams from the beam scanner on to the sample;
a photodetector including an array of N by M detector elements respectively associated with the time multiplexed N by M beams,
the photodetector detecting fluorescence signals from the sample; and

a processor coupled to the photodetector and operable to process output signals from the photodetector according to the illumination
cycle such that in any phase, only output signals from non-neighboring detector elements are read.

US Pat. No. 9,309,236

PI-KINASE INHIBITORS WITH BROAD SPECTRUM ANTI-INFECTIVE ACTIVITY

The Board of Trustees of ...

1. A compound of the structure:
wherein:
R1 is selected from an aryl, a heterocycle, and a cycloalkyl;

R2 is selected from hydrogen, a halogen, an alkyl and an alkoxy;

R3 is an alkyl;

R4 is an alkyl, an alkyl-cycloalkyl, or an alkyl-heterocyclyl;

W1 is —SO2—; and

W2 is —NHCO—.

US Pat. No. 9,136,363

COMPOUND TUNNELING FIELD EFFECT TRANSISTOR INTEGRATED ON SILICON SUBSTRATE AND METHOD FOR FABRICATING THE SAME

Kyungpook National Univer...

1. A compound tunneling field effect transistor comprising:
a silicon substrate;
a source region formed of a first semiconductor material having a lattice constant difference with silicon 5% or less, a bandgap
at least 0.4 electron volts (eV) narrower than that of silicon and a first conductive type on the silicon substrate;

a channel region formed of a second semiconductor material having a lattice constant difference with the first semiconductor
material 2% or less, a bandgap wider than that of the first semiconductor material and electron mobility at least 5 times
higher than that of silicon on the source region;

a drain region formed of a third semiconductor material having a lattice constant difference with the second semiconductor
material 1% or less, a bandgap wider than or equal to that of the second semiconductor material and a second conductive type
opposite to the first conductive type on the channel region;

a gate dielectric layer formed on a sidewall of the channel region; and
a gate electrode formed on the gate dielectric layer, wherein a vertical channel is further included.

US Pat. No. 9,386,682

DISTRIBUTED COUPLING AND MULTI-FREQUENCY MICROWAVE ACCELERATORS

The Board of Trustees of ...

1. A microwave circuit for a linear accelerator, the microwave circuit comprising multiple metallic cell sections,
a pair of distribution waveguide manifolds, and
a sequence of feed arms connecting the manifolds to the cell sections;
wherein the distribution waveguide manifolds are connected to the cell sections so that alternating pairs of cell sections
are connected to opposite distribution waveguide manifolds, wherein the distribution waveguide manifolds have concave modifications
of their walls opposite the feed arms, and wherein the feed arms have portions of two distinct widths.

US Pat. No. 9,320,724

METHOD OF IMPROVING COGNITION AND INCREASING DENDRITIC COMPLEXITY IN HUMANS WITH DOWN SYNDROME AND COMPOSITIONS THEREFOR

The Board of Trustees of ...

1. A method of improving cognitive functioning in a human having Down syndrome, comprising administering an effective amount
of a ?2 adrenergic receptor agonist capable of crossing the human blood-brain barrier or a pharmaceutically acceptable salt
thereof in combination with a ?1 adrenergic receptor antagonist incapable of crossing the human blood-brain barrier or a pharmaceutically
acceptable salt thereof to the human thereby improving the cognitive functioning of said human, wherein the ?2 adrenergic
receptor agonist is more selective for ?2 adrenergic receptors than for ?1 adrenergic receptors.

US Pat. No. 9,320,832

ELECTROCHEMICAL DISINFECTION OF IMPLANTED CATHETERS

SRI INTERNATIONAL, Menlo...

1. A method for electrochemically disinfecting a catheter implanted in a patient's body, by creating a biofilm-inhibiting
concentration of oxidizing agents, the catheter comprising:
an elongate catheter body comprising a dielectric material and having a proximal region, a distal region, a lumen extending
through the catheter body and adapted to transport fluid from the proximal region to the distal region, an outer surface on
the exterior of the catheter body, and an inner surface on the interior of the lumen, and

at least two exterior electrodes on and integral with the outer surface of the catheter, the exterior electrodes being elongate
and extending longitudinally along the outer surface of the catheter body from the proximal region to the distal region, wherein
the exterior electrodes extend radially inward from the outer surface through a wall of the catheter body to the inner surface,
thereby additionally serving as interior electrodes;

wherein the two exterior electrodes are separated by a pair of gaps, each gap comprising the dielectric material of the catheter
body, and extending radially from the outer surface to the inner surface of the catheter body and longitudinally from the
proximal region to the distal region;

the method comprising, in the absence of an added biocidal agent, with the catheter implanted in the patient's body, and without
removing the catheter from the patient's body, applying a voltage across the exterior electrodes of a magnitude that is effective
to create a biofilm-inhibiting concentration of oxidizing agents from endogenous compounds present in the body.

US Pat. No. 9,305,267

SIGNAL DETECTION ALGORITHMS TO IDENTIFY DRUG EFFECTS AND DRUG INTERACTIONS

The Board of Trustees of ...

1. A computer-implemented method for detection of latent signals in adverse event information, comprising:
receiving a set of drug and event information that includes a first set of adverse event information and further includes
prescription and morbidity information;

identifying a second set of events associated with the first set of adverse events;
computing covariances in drug co-prescription from the set of drug and event information;
computing covariances in co-morbities from the set of drug and event information;
approximating adverse event biases based on the covariances in drug co-prescription and comorbidities;
applying a statistical analysis to the second set of events to determine a subset of the second set of events that occurs
above a predetermined level with the first set of adverse events, wherein the statistical analysis is corrected based on the
approximated adverse event biases;

receiving a training dataset that includes drug and event information;
training a predictive model using the subset of the second set of events and the training dataset, wherein the predictive
model is trained to detect a detected set of adverse events; and

applying the predictive model to a test dataset to determine the detected set of adverse events.

US Pat. No. 9,280,003

MULTIMODE FIBER FOR SPATIAL SCANNING

The Board of Trustees of ...

1. An apparatus comprising:
a first optical fiber operative for receiving a first light signal at a first input facet and providing a second light signal
at a first output facet, the first optical fiber supporting a first plurality of optical modes that collectively define the
second light signal;

a first spatial light modulator, the first spatial light modulator being operative for providing the first light signal to
the first input facet and controlling at least one of the relative phase and relative amplitude of each of the first plurality
of optical modes to control the shape of the second light signal and direct the second light signal to at least one of a plurality
of object points within a scan region;

a second spatial light modulator, the second spatial light modulator being operative for receiving a third light signal from
the first input facet and providing a fourth light signal, wherein the third light signal comprises light reflected from the
scan region into the first output facet, and wherein the second spatial light modulator is operative for manipulating the
phase configuration of the third light signal to selectively pass light from one of the plurality of object points to a power
monitor; and

a first sensor located within the scan region, wherein the first sensor provides a first sensor signal when the second light
signal is incident on it.

US Pat. No. 9,309,556

DIRECT CAPTURE, AMPLIFICATION AND SEQUENCING OF TARGET DNA USING IMMOBILIZED PRIMERS

The Board of Trustees of ...

1. A method of capturing and amplifying a selected sequence comprising:
a) obtaining a substrate comprising a first population of surface-bound oligonucleotides and a second population of surface-bound
oligonucleotides, wherein the members of said first and second populations of surface-bound oligonucleotides are attached
to the same substrate but not spatially addressed on said substrate;

b) hybridizing a first member of said first population of surface-bound oligonucleotides to a selection oligonucleotide comprising
a region that hybridizes with said first member and a region that contains a genomic sequence,

c) extending said first member of said first population of surface-bound oligonucleotides using the hybridized selection oligonucleotide
of (b) as a template to produce an extended support-bound selection primer that comprises a sequence that is complementary
to said genomic sequence;

d) hybridizing said extended support-bound selection primer of step c) to denatured fragmented genomic DNA to produce a duplex
comprising said extended support-bound selection primer and a strand of genomic DNA that comprises said genomic sequence,
wherein, in the duplex, the strand of genomic DNA is at least 100 bases in length and the 3? end of the extended support-bound
selection primer is extendible using the strand of genomic DNA as a template;

e) extending said extended support-bound selection primer using the strand of genomic DNA as a template to produce an extension
product that contains the complement of a sequence that flanks said genomic sequence; and

f) amplifying said extension product of step e) on said substrate by bridge PCR using unextended members of said first and
second populations of surface-bound oligonucleotides of step a), to produce a PCR product.

US Pat. No. 9,095,455

BRAIN MACHINE INTERFACES INCORPORATING NEURAL POPULATION DYNAMICS

The Board of Trustees of ...

1. A brain-machine interface for restoring motor function, comprising:
(a) a neural implant for obtaining neural observations yk, wherein the neural observations are defined by a spike frequency of one or more neurons;

(b) a computer-implemented inference system for inferring a neural dynamical state sk from the obtained neural observations (yk), wherein the inferred neural dynamical state is a state of a dynamical system which is defined by:

sk+1=f(sk)+g(uk)+nk
yk=h(sk)+l(uk)+rk
 where f(sk) is a function describing how the neural dynamical state evolves over time from sk to sk+1,

where h(sk) is a function mapping the neural dynamical state sk to the neural observations yk,

where (uk) is an input to the dynamical system at time k,

where g(uk) is a function mapping the input uk to the dynamical state Sk+1,

where l(uk) is a function mapping the input uk to the neural observations yk,

where nk and rk are noise variables, and

where k denotes time;
(c) a prosthetic device; and
(d) a controller interfaced with the prosthetic device, wherein the inferred neural dynamical state (sk) is input to the controller to control kinematic variables (xk) of the prosthetic device.

US Pat. No. 9,206,221

AMPHIPHILIC COMPOUNDS

Wisconsin Alumni Research...

1. A compound of Formula V:
wherein
L is —(CH2)n— where n is 1-12, or a direct bond;

X is a direct bond, NH or O;
Y is O or absent;
Z is H, methyl, ethyl, propyl, or butyl;
the dashed line represents an optionally present double bond; and
each Sac is independently an oxygen-linked monosaccharide, disaccharide, or trisaccharide.
US Pat. No. 9,382,314

MODULATION OF SYNAPTIC MAINTENANCE

The Board of Trustees of ...

1. A method of treating a patient afflicted with a neurodegenerative disorder of the central nervous system, the method comprising
administering to the patient a therapeutic amount of a complement inhibitor to thereby treat the neurodegenerative disorder,
wherein the complement inhibitor is an antibody that binds to a component of the C1 complex, wherein the component of the
C1 complex is selected from the group consisting of C1q, C1s and C1r.

US Pat. No. 9,342,792

QUANTUM COMPUTER AND QUANTUM COMPUTING USING ISING MODEL

Inter-University Research...

1. A quantum computer using an ising model comprising:
a plurality of coherent oscillators that oscillate light having polarization polarized in a same direction determined in advance
in correspondence with a plurality of sites of the ising model;

a master oscillator that performs injection synchronization for the plurality of coherent oscillators and oscillates the light
having polarization polarized in the same direction determined in advance;

a master oscillator-to-coherent oscillator optical path unit that is arranged between the master oscillator and each one of
the coherent oscillators;

an inter-coherent oscillator optical path unit that is arranged between two coherent oscillators for each pair of the plurality
of the coherent oscillators;

an oscillation frequency control unit that is arranged in each master oscillator-to-coherent oscillator optical path unit
and controls an oscillation frequency of each one of the coherent oscillators so as to be an oscillation frequency of the
master oscillator;

an inter-coherent oscillator intensity control unit that is arranged in each inter-coherent oscillator optical path unit for
each pair of the plurality of the coherent oscillators and implements a magnitude of pseudo ising interaction between two
coherent oscillators by controlling an intensity of light exchanged between the two coherent oscillators;

an inter-coherent oscillator optical path length control unit that is arranged in each inter-coherent oscillator optical path
unit for each pair of the plurality of the coherent oscillators and implements a sign of the pseudo ising interaction between
two coherent oscillators by controlling an optical path length between the two coherent oscillators; and

an oscillation phase measuring unit that measures pseudo ising spins of the plurality of the coherent oscillators by measuring
relative values of oscillation phases of the plurality of the coherent oscillators with respect to the oscillation phase of
the master oscillator after the plurality of the coherent oscillators arrive at a steady state.

US Pat. No. 9,326,366

INTRA PULSE MULTI-ENERGY METHOD AND APPARATUS BASED ON RF LINAC AND X-RAY SOURCE

The Board of Trustees of ...

1. A method for providing X-ray pulses having a controllable intra-pulse energy distribution, the method comprising:
providing a periodic train of electron bunches;
accelerating the electron bunches with a traveling radio frequency (RF) wave in a linear accelerator to provide accelerated
electron bunches;

providing the accelerated electron bunches to one or more targets to generate X-rays, wherein each output X-ray pulse includes
contributions from multiple electron bunches; and

controlling an amplitude of the traveling RF wave and/or a relative phase of the traveling RF wave and the train of electron
bunches to control the amount of energy provided to individual electron bunches, thereby providing controllable intra-pulse
energy distribution of the output X-ray pulses.

US Pat. No. 9,284,353

MAMMALIAN CODON OPTIMIZED NUCLEOTIDE SEQUENCE THAT ENCODES A VARIANT OPSIN POLYPEPTIDE DERIVED FROM NATROMONAS PHARAONIS (NPHR)

The Board of Trustees of ...

1. An isolated nucleic acid comprising a mammalian codon optimized nucleotide sequence that encodes a variant opsin polypeptide
derived from Natromonas pharaonis (NpHR), wherein the variant NpHR polypeptide comprises a heterologous endoplasmic reticulum (ER) export signal comprising
the amino acid sequence set forth in SEQ ID NO: 16, wherein the variant NpHR polypeptide inhibits depolarization of a neuron
in response to light of a wavelength that activates the variant NpHR polypeptide, and wherein the variant NpHR polypeptide
exhibits reduced toxicity in the neuron compared to toxicity induced by wild-type NpHR.

US Pat. No. 9,398,681

DISTRIBUTED COUPLING HIGH EFFICIENCY LINEAR ACCELERATOR

The Board of Trustees of ...

1. A microwave circuit for a linear accelerator, the microwave circuit comprising multiple monolithic metallic cell plates,
a distribution waveguide, and a sequence of feed arms;
wherein the cell plates are stacked upon each other and grouped to form a sequence of cell sections;
wherein each of the feed arms has two slots coupled symmetrically on opposite sides of the distribution waveguide, wherein
the two slots are coupled to adjacent cell sections.

US Pat. No. 9,362,568

BATTERY WITH HYBRID ELECTROCATALYSTS

The Board of Trustees of ...

1. An apparatus comprising:
a nanocarbon substrate including at least one of graphene and carbon nanotubes (CNTs); and
a hybrid electrode including a cobalt oxide/carbon nanotube (CoO/CNT) catalyst and a Ni—Fe-layered double hydride (LDH) catalyst,
the electrode being configured and arranged to facilitate transfer of charge carriers with the nanocarbon substrate.

US Pat. No. 9,303,289

PHASED GENOME SEQUENCING

The Board of Trustees of ...

1. A method comprising:
fragmenting a chromosome into chromosomal fragments;
contacting chromosomal fragments with a plurality of oligonucleotide probes, wherein the oligonucleotide probes contain a
fluorescent signal, wherein the oligonucleotide probes bind to a nucleic acid comprising a nucleic acid sequence of interest,

isolating chromosomal fragments based on the fluorescent signal by using a fluorescence activated cell sorter, wherein the
isolated chromosomal fragments associated with the fluorescent signal are separated from chromosomal fragments not associated
with the fluorescent signal, wherein the isolating comprises collecting the isolated chromosomal fragments associated with
the signal into separate containers each container containing no more than one chromosomal fragment;

sequencing the isolated fragments associated with the fluorescent signal to obtain sequence of the chromosomal fragment containing
the nucleic acid sequence of interest.

US Pat. No. 9,115,184

LIGHT-INDUCIBLE SYSTEM FOR REGULATING PROTEIN STABILITY

The Board of Trustees of ...

1. A light-regulated conditional protein stability system, comprising:
a nucleic acid sequence encoding a fusion protein comprising a protein of interest fused in-frame to a light-regulated, stability-affecting
polypeptide comprised of a light-sensitive degradation domain and a degron peptide selected from the group consisting of peptides
identified as SEQ ID NO: 2, SEQ ID NO: 9 and SEQ ID NO: 10,

wherein, upon introduction of the nucleic acid sequence to a cell, the fusion protein is expressed and stability of the fusion
protein is modulated by exposure of the cell to a non-toxic light.

US Pat. No. 9,079,859

SYNTHETIC LETHAL TARGETING OF GLUCOSE TRANSPORT

AUCKLAND UNISERVICES LIMI...

1. A method for inhibiting cell growth or proliferation of a cell that is HIF pathway proficient comprising contacting a cell
wherein the cell is HIF pathway proficient with a therapeutic entity, wherein the therapeutic entity inhibits the activity
of GLUT1 and wherein the therapeutic entity preferentially inhibits the growth or proliferation of neoplastic cells versus
normal cells.
US Pat. No. 9,364,484

METHODS AND COMPOSITIONS FOR TREATING VIRAL DISEASES

The Board of Trustees of ...

1. A method of inhibiting infections by a Lentiviridae, HIV, HCV/HIV co-infection, Flaviviridae other than HCV, clathrin AP
binding viruses other than Flaviviridae, or clathrin AP binding viruses other than HCV, the method comprising administering
to a patient in need thereof an effective amount of sunitinib or a pharmaceutically acceptable salt of sunitinib.

US Pat. No. 9,329,252

APPARATUS FOR REAL-TIME PHASE CORRECTION FOR DIFFUSION-WEIGHTED MAGNETIC RESONANCE IMAGING USING ADAPTIVE RF PULSES

The Board of Trustees of ...

1. A method of performing diffusion weighted magnetic resonance imaging (MRI), the method comprising:
a) operating an MRI system in order to provide a navigator image of an imaging subject, wherein the MRI system comprises:
an MRI system processor,
a main magnet configured to provide a main magnetic field,
one or more gradient magnets configured to provide controllable magnetic field gradients, and
one or more radio-frequency (RF) sources of RF emission configured to provide controllable RF pulses;
b) computing, in real time with the MRI system processor, a phase error map from the provided navigator image;
c) determining, in real time with the MRI system processor, an adaptive RF pulse from the computed phase error map that compensates
for phase errors of the computed phase error map;

d) determining, in real time with the MRI system processor, one or more adaptive magnetic field gradients corresponding to
the computed phase error map and the determined adaptive RF pulse;

e) providing the determined adaptive RF pulse to the imaging subject with the one or more sources of RF emission and simultaneously
providing the determined adaptive magnetic field gradients to the imaging subject with the one or more gradient magnets; and

f) performing diffusion-weighted MRI of the imaging subject by performing steps a) through e) above in succession one or more
times while recording, displaying and/or storing the diffusion weighted magnetic resonance imaging scan results.

US Pat. No. 9,347,073

MINI-INTRONIC PLASMID VECTORS

The Board of Trustees of ...

1. A mini-intronic plasmid (MIP) vector, comprising an expression cassette comprising:
(a) a promoter operably linked to a transgene,
(b) an intronic cassette comprising an intron, wherein the intron: (i) comprises a bacterial origin of replication and a selectable
marker, (ii) is flanked by a splice donor sequence at its 5? end and a splice acceptor sequence at its 33? end, and (iii) is operably linked to said promoter, and

(c) a termination sequence,
wherein the MIP vector comprises less than 1 kb of nucleotide sequence external to the expression cassette and does not comprise
a bacterial origin of replication or a selectable marker external to the intron.

US Pat. No. 9,177,748

PULSED DEPRESSED COLLECTOR

The Board of Trustees of ...

1. A high power RF device comprising:
an electron beam cavity having a cathode, an anode, and a multi-stage depressed collector;
a modulator configured to provide pulses to the cathode; and
a circuit connected to the modulator and to electrode stages of the multi-stage depressed collector,
wherein the circuit comprises a storage capacitor that dynamically biases potentials of the electrode stages of the multi-stage
depressed collector and provides recovered energy from the electrode stages of the multi-stage depressed collector to the
modulator.

US Pat. No. 9,368,579

SELECTIVE AREA GROWTH OF GERMANIUM AND SILICON-GERMANIUM IN SILICON WAVEGUIDES FOR ON-CHIP OPTICAL INTERCONNECT APPLICATIONS

The Board of Trustees of ...

1. A method for monolithic integration of dissimilar semiconductor materials, the method comprising:
providing a substrate comprising a first semiconductor layer and one or more primary protective layers disposed on the first
semiconductor layer;

etching through the primary protective layers into the first semiconductor layer to provide a trench having side walls and
a bottom;

laterally undercutting at least one of the protective layers by selectively etching the side walls with a side wall etch that
preferentially etches the first semiconductor layer with respect to the protective layers;

forming a secondary protective layer on the side walls and bottom of the trench;
removing the secondary protective layer from the bottom of the trench with a bottom layer etch that completely removes the
secondary protective layer on the bottom of the trench and does not completely remove the secondary protective layer on the
side walls of the trench; and

growing a second semiconductor in the trench, wherein the first semiconductor layer and the second semiconductor have distinct
compositions;

wherein the substrate comprises a silicon on insulator wafer having a buried oxide layer sandwiched between a silicon substrate
and a top silicon layer;

wherein the bottom of the trench is in the top silicon layer.
US Pat. No. 9,365,628

OPSIN POLYPEPTIDES AND METHODS OF USE THEREOF

The Board of Trustees of ...

1. An isolated fusion polypeptide comprising an amino acid sequence having at least 85% amino acid sequence identity to the
amino acid sequence set forth in SEQ ID NO: 22, wherein said polypeptide is fused to an endoplasmic reticulum (ER) export
sequence and/or a trafficking sequence.

US Pat. No. 9,337,169

ENVIRONMENTALLY-ASSISTED TECHNIQUE FOR TRANSFERRING DEVICES ONTO NON-CONVENTIONAL SUBSTRATES

The Board of Trustees of ...

1. A device fabrication method, comprising:
providing a growth substrate including an oxide layer;
forming a metal layer over the oxide layer;
forming a stack of device layers over the metal layer;
performing fluid-assisted interfacial debonding of the metal layer to separate the stack of device layers and the metal layer
from the growth substrate; and

affixing the stack of device layers to a target substrate.

US Pat. No. 9,308,011

SURGICAL DEVICE AND METHODS

THE BOARD OF TRUSTEES OF ...

20. A device for surgery comprising:
an introducer rod or delivery system comprising an introducer distal end for introduction into a target site;
an end effector including a working tool, and a rotating-locking element comprising a first connector and a second connector,
and wherein the end effector is attached to the working tool; and

a control element comprising a control shaft including a distal end for introduction into the target site;
wherein the rotating-locking element is rotatable in a first direction relative to the end effector such that the first connector
locks the end effector to the introducer distal end outside of a target site such that the introducer can deliver the end
effector into the target site, and wherein the rotating-locking element is rotatable in a second direction to simultaneously
both cause the second connector to lock the end effector to the distal end of the control shaft of the control element in
the target site and cause the first connector to unlock the end effector from the introducer distal end.

US Pat. No. 9,287,598

RF WINDOW ASSEMBLY COMPRISING A CERAMIC DISK DISPOSED WITHIN A CYLINDRICAL WAVEGUIDE WHICH IS CONNECTED TO RECTANGULAR WAVEGUIDES THROUGH ELLIPTICAL JOINTS

The Board of Trustees of ...

1. A high-power microwave RF window, comprising:
a. a cylindrical waveguide, wherein said cylindrical waveguide comprises a ceramic disk concentrically housed in a central
region of said cylindrical waveguide;

b. a first rectangular waveguide, wherein said first rectangular waveguide is connected by a first elliptically-shaped joint
to a proximal end of said cylindrical waveguide; and

c. a second rectangular waveguide, wherein said second rectangular waveguide is connected by a second elliptically-shaped
joint to a distal end of said cylindrical waveguide, wherein said elliptically-shaped joint spans from a flat surface of said
rectangular waveguide to a wall of said cylindrical waveguide, wherein said elliptically-shaped joint is disposed to create
a traveling wave inside said ceramic disk and disposed to minimize an electric field on a surface of said ceramic disk and
disposed to minimize an electric field inside said ceramic disk.

US Pat. No. 9,248,049

SKIN TREATMENT DEVICES AND METHODS WITH PRE-STRESSED CONFIGURATIONS

The Board of Trustees of ...

32. A system for treating a patient, comprising:
a silicone layer having a durometer in a range of 30 to 50 and a thickness in a range of 100 microns to 500 microns, wherein
the silicone layer has a relaxed configuration and a strained configuration, the strained configuration having a predetermined
strain;

a polymeric backing layer attached to the silicone layer;
an adhesive layer attached to the silicone layer, the adhesive layer comprising a pressure sensitive adhesive configured to
resist relaxation of the silicone layer for at least 24 hours, the pressure sensitive adhesive having a T-peel release force
test value greater than 125 kg/m and a blunt probe tack test value greater than 0.45 kg; and

a mechanism configured to releasably maintain the silicone layer in its strained configuration.

US Pat. No. 9,234,240

MEASUREMENT AND COMPARISON OF IMMUNE DIVERSITY BY HIGH-THROUGHPUT SEQUENCING

THE BOARD OF TRUSTEES OF ...

1. A method of characterizing an immune repertoire of an organism, comprising:
a) obtaining mRNA from a biological sample comprising B cells of the organism;
b) producing cDNA from the mRNA obtained in Step (a);
c) producing amplicons from the cDNA produced in Step (b), wherein the amplicons are produced using a set of primers that
amplify a plurality of immunoglobulin heavy chain VDJ exon sequences, wherein said amplicons comprise both the VD junction
and the DJ junction;

d) sequencing amplicons produced in Step (c) using massively-parallel sequencing to obtain at least 104 sequence reads of immunoglobulin heavy chain sequences, comprising sequences from a plurality of different genomic V segments,
a plurality of different genomic D segments, and a plurality of different genomic J segments;

e) comparing sequences obtained in Step (d) to known sequences associated with immune function, wherein said known sequences
comprise a plurality of genomic heavy chain V-segment sequences of the organism, wherein said comparing step comprises compiling
sequence data on a computer-readable medium and processing said data on said computer to identify regions of similarity and
difference between said sequences obtained in Step (d) and said known sequences;

f) grouping sequences obtained in Step (d) based on the comparison in Step (e) to identify a plurality of groups of heavy
chain VDJ sequences;

g) clustering heavy chain VDJ sequences within individual groups from Step (f) to define a plurality of clusters;
h) determining consensus sequences for individual clusters, wherein the consensus sequences correspond to heavy chain VDJ
segments of the organism's immune repertoire, and wherein the consensus sequences have reduced amplification bias and sequencing
error compared to the sequence data of Step (d); and

i) identifying somatic mutations in the heavy-chain VDJ exon sequences using the consensus sequences;
thereby to characterize the organism's immune repertoire.

US Pat. No. 9,233,089

TREATMENT OF PULMONARY HYPERTENSION WITH LEUKOTRIENE INHIBITORS

The Board of Trustees of ...

1. A method of treating pulmonary arterial hypertension in a subject in need thereof, said method comprising administering
to said subject (2S)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoic acid or a pharmaceutically acceptable
salt thereof at a daily dose of 100-200 mg/day, wherein the daily dose is administered on consecutive days for at least a
month.

US Pat. No. 9,449,249

METHOD AND APPARATUS FOR ENHANCING VISUAL SEARCH

Nokia Corporation, Espoo...

1. A method comprising:
identifying one or more features of a source query image for a visual search;
generating, with a processor, a histogram map comprising one or more histogram bins, wherein the histogram map represents
the location of the one or more features of the source query image; and

generating a context for at least one of the one or more histogram bins, wherein the context comprises a first context value
based on information related to one or more neighboring bins located a first distance from the respective histogram bin and
a second context value based on information related to one or more neighboring bins located a second distance from the respective
histogram bin, wherein the first context value comprises a count of the one or more neighboring bins located a first distance
front the respective histogram bin containing one or more features, and the second context value comprises a count of the
one or more neighboring bins located a second distance front the respective histogram bin containing one or more features.

US Pat. No. 9,281,091

METHOD AND STRUCTURE FOR PLASMONIC OPTICAL TRAPPING OF NANO-SCALE PARTICLES

The Board of Trustees of ...

1. An article comprising:
a coaxial plasmonic aperture, wherein the coaxial plasmonic aperture includes:
a core, wherein the core comprises a metal;
a channel, wherein the channel surrounds the core, and wherein the channel comprises a dielectric and has a width in a range
of about 5 nanometers to about 500 nanometers; and

a cladding, wherein the cladding surrounds the channel and comprises metal; and
a laser, wherein the laser is positioned to illuminate a first end of the coaxial plasmonic aperture, the first end being
an input end.

US Pat. No. 9,121,915

MULTI-DIMENSIONAL CARDIAC AND RESPIRATORY IMAGING WITH MRI

The Board of Trustees of ...

1. A 5-dimensional magnetic resonance (MR) imaging method of a patient's heart, comprising:
(a) in a patient free-breathing magnetic resonance imaging study of said patient's heart, a magnetic resonance imaging (MRI)
computer system acquiring 3-dimensional volumetric spatial information of said patient's heart and concurrently recording
cardiac and respiratory cycles of said patient, wherein said 3-dimensional volumetric spatial information is sampled with
a non-Cartesian 3-dimensional k-space readout trajectory which is incorporated into a magnetic resonance imaging sequence,
wherein said MRI computer system acquisition comprises a plurality of MRI acquisition segments of a plurality of readouts
of said heart, whereby each segment is repeated multiple times in order to cover the at least a full period of a cardiac cycle
and at least a full period of a respiratory cycle of said patient, wherein the MRI computer system combines the acquired 3-dimensional
volumetric spatial information of the non-Cartesian 3-dimensional K-space readout trajectory in the MRI sequence with the
plurality of readouts of the heart representing said at least full period of the cardiac cycle and said at least full period
respiratory cycle, whereby the plurality of readouts of said heart for both the cardiac and respiratory cycles are defined
as 2-dimensional non-spatial information in order to form a 5-dimensional data map of the patient's heart; and

(b) for each cardiac and respiratory temporal phase combination in said recorded cycles, said MRI computer system displaying
at least one of the 3-dimensional volumetric spatial measurements of the atria and ventricles of said patient's heart, together
with either the rate of change, minimum, maximum, or slope of these volume based measurements with respect to each of said
cardiac and respiratory cycles, wherein the MRI system computer displays 3 of the 5 dimensions that are selected from the
5-dimensional data map, and wherein at least one non-spatial dimension is displayed as one of the 3 dimensions selected from
the 5-dimensional data map that is displayed.

US Pat. No. 9,074,192

INHIBITION OF AXL SIGNALING IN ANTI-METASTATIC THERAPY

THE BOARD OF TRUSTEES OF ...

1. An isolated soluble AXL variant polypeptide, wherein said polypeptide lacks the AXL transmembrane domain and has an amino
acid substitution relative to the wild-type AXL sequence (SEQ ID NO.1) of alanine 72 to valine, and wherein said substitution
increases the affinity of the AXL polypeptide binding to GAS6.
US Pat. No. 9,410,170

METHODS OF IN VITRO PROTEIN SYNTHESIS

THE BOARD OF TRUSTEES OF ...

1. A method for synthesis of polynucleotides and/or polypeptides in a cell-free reaction mixture initially comprising a bacterial
cell extract; a template for production of the polynucleotides and/or polypeptide; monomers for the polynucleotides and/or
polypeptide to be synthesized, and such co-factors, enzymes and other reagents that are necessary for the synthesis; the method
comprising:
synthesizing said polynucleotides and/or polypeptides in a cell-free reaction mixture modified to include:
at least 10 mM of a phosphate-free energy source wherein said phosphate free energy source is glucose or glutamate; nucleoside
monophosphates in the absence of exogenous nucleoside triphosphates; and exogenous inorganic phosphate salts at a concentration
of at least about 1 mM.

US Pat. No. 9,388,238

MODULATION OF SYNAPTIC MAINTENANCE

The Board of Trustees of ...

1. A method of treating glaucoma, the method comprising administering a therapeutic amount of a complement inhibitor to a
patient suffering from glaucoma to thereby treat the glaucoma, wherein the complement inhibitor is an anti-C1s antibody.

US Pat. No. 9,362,227

TOPOLOGICAL INSULATOR IN IC WITH MULTIPLE CONDUCTOR PATHS

The Board of Trustees of ...

1. An electrical circuit comprising:
a first circuit (22) generating a first current signal;

a second circuit (24) generating a second current signal;

a magnetically doped, topological insulator (26) formed of a plurality of layers (26A-26X), each layer of the topological insulator having conductive edges with insulating properties between the edges, a first
edge of the topological insulator forming a first set of edges of the layers, and a second edge of the topological insulator
forming a second set of edges of the layers;

a first electrode contacting the first set of edges;
a second electrode contacting the second set of edges;
the first current signal being coupled to the first electrode; and
the second current signal being coupled to the second electrode,
wherein the first set of edges of the topological insulator comprises a first plurality of separate conduction paths, wherein
the first plurality of separate conduction paths are electrically connected in parallel by the first electrode, and

wherein the second set of edges of the topological insulator comprises a second plurality of separate conduction paths, wherein
the second plurality of separate conduction paths are electrically connected in parallel by the second electrode.

US Pat. No. 9,205,261

NEUROSTIMULATION METHODS AND SYSTEMS

The Board of Trustees of ...

1. A method of stimulating a target dorsal root ganglion of a patient, comprising:
implanting at least one electrode in proximity to the target dorsal root ganglion; and
activating the at least one electrode to deliver neurostimulation energy to at least a portion of the target dorsal root ganglion,
without passing the neurostimulation energy through an intervening physiological structure, to selectively stimulate at least
a portion of the target dorsal root ganglion to create paresthesia in an area of the patient's body.

US Pat. No. 9,101,628

METHODS AND COMPOSITION OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION

The Board of Trustees of ...

1. A method of treating a subject infected with a Hepatitis C virus, the method comprising administering to said subject clemizole,
or a pharmaceutically acceptable salt, an isomer, or a tautomer, in combination with an HCV NS3 protease inhibitor selected
from the group consisting of boceprevir and telaprevir, in an amount that is effective in reducing viral load of said virus
in said subject.

US Pat. No. 9,314,279

SYSTEMS AND METHODS FOR POSTERIOR DYNAMIC STABILIZATION OF THE SPINE

The Board of Trustees of ...

1. An interspinous device for stabilizing at least one spinal motion segment comprising a first vertebra having a first spinous
process and a second vertebra having a second spinous process, the device comprising:
a member having a length and a diameter and being deployable from a first configuration to a second configuration, wherein
one of the length and the diameter of the member in the first configuration is changed when the member is in the second configuration,
and wherein the member includes a central section,

first and second end portions spaced apart to receive the first and second spinous processes therebetween, wherein the first
and second end portions are configured to move along opposite sides of the first spinous process and to move along opposite
sides of the second spinous process when the central section is positioned directly between the first and second spinous processes
and the member moves from the first configuration to the second configuration, and

wherein the central section is configured to be positioned between the first and second end portions such that the first and
second end portions extend away from the central section when the member is in the second configuration, and wherein the central
section is configured to contact and gradually push apart the first and second spinous processes when the member moves toward
the second configuration for distracting the first and second spinous processes and when the central section extends transversely
across the first and second spinous processes.

US Pat. No. 9,281,415

PRESSURE SENSING APPARATUSES AND METHODS

The Board of Trustees of ...

1. An apparatus comprising:
a dielectric structure including a plurality of elastomeric regions separated from one another by space regions and each of
the elastomeric regions characterized by common feature dimensions including width and thickness dimensions, each of the elastomeric
regions being separated from one another and configured and arranged with such common feature dimensions to respond to pressure
applied to the dielectric structure by compressing and thereby exhibit a changed effective dielectric constant of elastomeric
material in the elastomeric region, the changed effective dielectric constant corresponding to a state of compression of the
elastomeric regions; and

a sense circuit including a plurality of impedance-based sensors, each impedance-based sensor including a portion of the dielectric
structure and being configured and arranged to respond to the changed effective dielectric constant by providing an indication
of the pressure applied to the dielectric structure adjacent each sensor, the pressure being indicated by a change in impedance,

wherein one or more of the elastomeric regions have a cross-sectional width dimension of less than 5 microns, and are configured
and arranged with the space regions and the sense circuit to provide respective outputs from each elastomeric region that
characterize pressure differences between the elastomeric regions of less than 1 kPa.

US Pat. No. 9,304,213

X-RAY POSITION DETECTOR AND IMPLEMENTATION IN A MIRROR POINTING SERVO SYSTEM

The Board of Trustees of ...

1. An X-ray beam position and stability detector, comprising:
a. a charged first metal blade and a charged second metal blade, wherein said charged first metal blade is collinear with
said charged second metal blade, wherein an edge of said charged first metal blade is opposite an edge of said charged second
metal blade, wherein said charged first metal blade edge and said charged second metal blade edge are disposed along a centerline
with respect to each other, wherein said charged metal blades are capable of photoelectron emission when exposed to an x-ray
beam;

b. a metal coating on said charged metal blades, wherein said metal coating is capable of i) enhancing said photoelectron
emission, or ii) suppressing energy-resonant contaminants, or iii) enhancing said photoelectron emission and suppressing energy-resonant
contaminants;

c. an entrance plate comprising an entrance aperture and an exit plate comprising an exit aperture;
d. a first carbon electrode, a second carbon electrode and a third carbon electrode, wherein said first carbon electrode and
said second carbon electrode surround said charged first metal blade, wherein said second carbon electrode and said third
carbon electrode surround said charged second metal blade, wherein said charged first metal blade is disposed in a first electric
field formed by said first carbon electrode and said second carbon electrode, wherein said charged second metal blade is disposed
in a second electric field formed by said second carbon electrode and said third carbon electrode, wherein said first carbon
electrode is adjacent to said entrance plate, wherein said third carbon electrode is adjacent to said third carbon electrode;
and

e. a photoelectron emission detector operated by an appropriately programmed computer, wherein said photoelectron emission
detector comprises an amplifier, wherein said amplifier is capable of detecting said photoelectron emission as a current signal.

US Pat. No. 9,296,621

DOPING AND REDUCTION OF NANOSTRUCTURES AND THIN FILMS THROUGH FLAME ANNEALING

The Board of Trustees of ...

1. A sol-flame method, comprising:
forming a sol-gel precursor solution of a source of a dopant;
coating a nanostructure or a thin film with the sol-gel precursor solution; and
subjecting the coated nanostructure or the coated thin film to flame annealing to form a doped nanostructure or a doped thin
film,

wherein a concentration of the dopant at a surface of the doped nanostructure or the doped thin film is at least 5 at. %,
and a concentration of the dopant at a depth of 10 nm below the surface is at least 50% of the concentration of the dopant
at the surface.

US Pat. No. 9,226,918

METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING NARCOTIC WITHDRAWAL SYMPTOMS

The Board of Trustees of ...

1. A method for treating physical dependence and/or withdrawal symptoms associated with narcotic use, comprising administering
to a human subject in need thereof a pharmaceutical composition consisting essentially of
(1) a narcotic compound selected from the group consisting of morphine, hydrocodone, oxycodone, hydromorphone, and oxymorphone,
buprenorphine and a combination of buprenorphine and naloxone, wherein said composition is administered at a dose of between
2 and 25 mg/70 kg of subject; and

(2) a 5-HT3 receptor antagonist in a dose effective to reduce physical dependence and/or withdrawal symptoms associated with
said narcotic use, wherein

the narcotic compound and the 5-HT3 receptor antagonist are co-administered.
US Pat. No. 9,365,837

PEPTIDE INHIBITORS OF PROTEIN KINASE C

The Board of Trustees of ...

1. A method for protecting cardiac tissue from damage due to an ischemic or hypoxic event comprising:
administering to a mammal in need thereof, a therapeutically effective amount of a peptide consisting of a contiguous sequence
of six to twelve amino acid residues that is at least 80% identical to a contiguous sequence of six to twelve amino acid residues
of a variable 5 (V5) domain of a delta protein kinase C (PKC) isozyme (SEQ ID NO:26), wherein the peptide is linked to a carrier
peptide, and wherein the peptide inhibits delta PKC isozyme activity.

US Pat. No. 9,265,738

SMALL MOLECULE CMKLR1 ANTAGONISTS IN DEMYELINATING DISEASE

The Board of Trustees of ...

1. A method of decreasing demyelinating inflammatory disease in a subject, the method comprising:
administering to said subject an effective amount of a compound of formula (I):
wherein
Q is selected from —NRQ4+, —NH4+, —NH2, —NHRQ, —NRQ2, —OH, —SH, and lower alkyl; wherein RQ is lower alkyl; and wherein; Q is selected from —NRQ4+ or —NH4+, then X? is present and is a counterion;

R1 and R2 are independently selected from hydrogen, alkyl, substituted alkyl, hydroxy, alkoxy, substituted alkoxy, amino, substituted
amino, carboxyl, carboxyl ester, cyano, halogen, acyl, aminoacyl, nitro, and sulfonyl; and

n is a number from one to four.
US Pat. No. 9,211,303

SELECTIVE REDUCTION OF THE DELETERIOUS ACTIVITY OF EXTENDED TRI-NUCLEOTIDE REPEAT CONTAINING GENES

National Yang-Ming Univer...

1. A method of selectively reducing the deleterious activity in a cell of a target gene comprising a mutant extended trinucleotide
repeat domain, the method comprising:
providing in the cell an effective amount of an agent that selectively reduces transcription of the mutant extended trinucleotide
repeat domain of the target gene in the cell to selectively reduce the deleterious activity of the target gene in the cell,
wherein the agent is a SPT4 protein inhibitory agent.

US Pat. No. 9,205,259

NEUROSTIMULATION SYSTEM

The Board of Trustees of ...

1. A system for stimulating a dorsal root ganglion within a body, the system comprising:
a lead comprising an elongate body having a plurality of electrodes disposed thereon, wherein the lead is configured for positioning
at least one of the plurality of electrodes within a distance of the dorsal root ganglion so as to provide selective stimulation
of the dorsal root ganglion; and

an implantable pulse generator connectable with the lead so as to provide stimulation energy to a selection of the plurality
of electrodes which provides stimulation to the dorsal root ganglion without intervening vertebral bone while selectively
stimulating the dorsal root ganglion.

US Pat. No. 9,191,026

IMAGE SENSOR AND IMAGING METHOD WITH SINGLE SHOT COMPRESSED SENSING

SONY CORPORATION, Tokyo ...

1. An image sensor comprising:
a plurality of pixel blocks including pixel elements, wherein each pixel element is configured to generate an analog signal
corresponding to an intensity of light impinged on the pixel element;

a plurality of analog to digital, A/D, converters connected to each of the pixel block, wherein each A/D converter is configured
to sample a corresponding average value of an input analog signal and convert the input analog signal to a digital signal
based on a predetermined activation code that determines which A/D converters of the plurality of A/D converters are activated;
and

a plurality of multiplexers, wherein each multiplexer is connected to the pixel block and the plurality of A/D converters
and is configured to sequentially select and distribute the analog signal and subsequent analog signals obtained from the
pixel block to the plurality of A/D converters in a cycle of A/D conversion.

US Pat. No. 9,355,470

METHOD AND SYSTEM FOR INTERACTIVE LAYOUT

The Board of Trustees of ...

1. A computer-implemented method for visually representing an arrangement of furniture, comprising:
receiving, by a computer, attributes for at least one room;
receiving, by the computer, attributes for one or more items of furniture to be placed in the at least one room;
receiving, by the computer, placement information for the one or more items of furniture;
generating, by the computer, at least one suggestion for placement of the one or more items of furniture in the room, wherein
the suggestions meet at least one predetermined design criteria and wherein one of the at least one predetermined design criteria
is computationally represented as terms in a density function; and

displaying, by the computer, one of the at least one suggestions for placement of the one or more items of furniture in the
room.

US Pat. No. 9,312,398

ENERGY STORAGE DEVICE WITH LARGE CHARGE SEPARATION

The Board of Trustees of ...

1. An energy storage system comprising:
1) a plasma-based energy storage device comprising:
first and second conductive electrodes spaced apart;
a first volume of active material disposed between the electrodes; and
a first volume of barrier material disposed between the first volume of active material and the first electrode; and
2) a source configured to illuminate the plasma-based energy storage device with electromagnetic radiation having a photon
energy greater than a band gap energy of the active material of the first active volume;

wherein upon application of a voltage across the electrodes one or both of an electron plasma or hole plasma is formed in
the first volume of active material;

wherein the electron plasma and/or hole plasma independently have a density of charge carriers of greater than about 0.5 carrier
per nm3 when the first volume of active material is subject to a field of 0.7 V/nm; and

wherein the voltage applied across the electrodes to form the plasma in the first volume of active material produces an energy
density of greater than about 1 Wh/L for the device.

US Pat. No. 9,278,159

LIGHT-ACTIVATED CATION CHANNEL AND USES THEREOF

The Board of Trustees of ...

1. A method of predicting potential ion channel modulating properties of a drug, the method comprising:
a) labeling a neuronal cell with a voltage sensitive dye, wherein the neuronal cell stably expresses a light-activated cation
channel protein and an ion channel of interest, wherein the light-activated cation channel protein comprises an amino acid
sequence having at least 75% amino acid sequence identity to ChR2;

b) exposing the neuronal cell to light, wherein the light is delivered at a frequency of at least 20 Hz;
c) monitoring the voltage sensitive dye to determine a first response in said cell;
d) exposing said dye-labeled neuronal cell to a candidate drug;
e) after exposing said cell to the candidate drug, further exposing said cell to light;
f) monitoring the voltage sensitive dye to determine a second response in said cell; and
g) comparing said first and second responses to identify a potential ion channel modulating property of said candidate drug,
wherein a second response that is higher than the first response indicates that the candidate drug modulates the ion channel.

US Pat. No. 9,275,844

APPARATUS AND METHOD FOR NANOFLOW LIQUID JET AND SERIAL FEMTOSECOND X-RAY PROTEIN CRYSTALLOGRAPHY

The Board of Trustees of ...

1. A method comprising:
providing a sample liquid by flowing a plurality of a first target of interest with a carrier liquid; and
injecting the sample liquid through a capillary tube at a rate of about 4 microliters per minute or less than 4 microliters
per minute, without a gas sheath flow, to form a cone or jet at a first position outside the capillary tube,

wherein
the first position is configured to intersect an X-ray beam;
the carrier liquid is electrically conductive; and
injecting the sample liquid further comprises injecting the sample liquid by applying a first voltage to the sample liquid
upstream of the first position and a different second voltage to a counter electrode downstream of the first position.

US Pat. No. 9,509,028

MICROBIAL BATTERIES WITH RE-OXIDIZABLE SOLID-STATE ELECTRODES FOR CONVERSION OF CHEMICAL POTENTIAL ENERGY INTO ELECTRICAL ENERGY

The Board of Trustees of ...

1. A method for converting chemical energy to electrical energy, the method comprising:
providing a microbial battery comprising:
an anode configured such that microbial activity at the anode provides electrons to an external circuit;
a cathode configured to receive the electrons from the external circuit and change its composition from an oxidized cathode
composition to a reduced cathode composition; and

a reaction chamber, wherein the anode and the cathode are disposed in an aqueous solution in the reaction chamber;
wherein the cathode is configured to be changed from the reduced cathode composition to the oxidized cathode composition in
a separate oxidation process outside the microbial battery;

i) operating the microbial battery until the cathode at least partially has the reduced cathode composition, thereby providing
a reduced cathode;

ii) removing the reduced cathode from the microbial battery;
iii) oxidizing the cathode until the cathode at least partially has the oxidized cathode composition, thereby providing an
oxidized cathode;

iv) adding the oxidized cathode to the microbial battery; and
repeating steps i, ii, iii, and iv in sequence one or more times.
US Pat. No. 9,453,065

PROTEIN BINDING DOMAINS STABILIZING FUNCTIONAL CONFORMATIONAL STATES OF GPCRS AND USES THEREOF

VIB VZW, Ghent (BE) Vrij...

1. A complex comprising:
a nanobody able to specifically bind to and stabilize an active conformational state of a beta 2 adrenergic receptor (?2AR), wherein the nanobody is able to enhance the affinity of the ?2AR for an agonist, and

?2AR in an active conformational state.

US Pat. No. 9,389,294

DISTORTION-FREE MAGNETIC RESONANCE IMAGING NEAR METALLIC IMPLANTS

The Board of Trustees of ...

1. A method for 3D magnetic resonance imaging (MRI) with slice-direction distortion correction in an MRI system comprising
a magnet system and a controller, comprising:
a) exciting by the magnet system one or more selective cross-sections with a thickness along a first axis using a RF pulse
with a bandwidth, wherein a selective cross-section is either a selective slice or selective slab;

b) applying by the magnet system a refocusing pulse to form a spin echo;
c) acquiring by the magnet system one or more 2D encoded image signals with readout along a second axis and phase encoding
along a third axis, wherein data along the phase encoded first and third axes is acquired with reduced sampling;

d) imaging by the controller a phase encoded volume by resolving a selective slice or selective slab position of the one or
more selective cross-sections by using phase encoding; and

e) suppressing by the controller the signal outside an image region along the phase encoded slice or slab in the first and
third axes.

US Pat. No. 9,354,335

DETERMINING LOCATION INFORMATION OF MICROSEISMIC EVENTS DURING HYDRAULIC FRACTURING

THE BOARD OF TRUSTEES OF ...

1. A method of processing an audio signal, comprising:
receiving the audio signal, the audio signal comprising an audio signal detected by a geophone placed in a well for monitoring
hydraulic fracturing, wherein the audio signal is received in accordance with a sampling rate and has a cutoff frequency defined
by the sampling rate;

compressing a dynamic amplitude range of the audio signal in accordance with a predefined ratio;
modifying the compressed audio signal using a nonlinear distortion operator to generate a modified audio signal, wherein the
modified audio signal has high frequency audible components not present in the received audio signal, comprising audible components
introduced by the nonlinear distortion operator in a predefined frequency range above the cutoff frequency defined by the
sampling rate of the received audio signal; and

sending the modified audio signal to an output configured for connection to a stereo or multi-channel speaker system, wherein
a user of the stereo or multi-channel speaker system is able to determine the locations of the microseismic events from listening
to the modified audio signals.

US Pat. No. 9,267,963

INTERFEROMETRIC ATOMIC-FORCE MICROSCOPY DEVICE AND METHOD

The Board of Trustees of ...

1. An atomic-force microscope system for estimating a physical property of a surface, the atomic-force microscope system including
a high-bandwidth AFM probe comprising:
a cantilever body that has a longitudinal axis along a first direction, wherein the cantilever body is characterized by a
first resonance frequency that is along a second direction that is substantially orthogonal with the first direction;

a sensor having a first end and a second end, the sensor and the cantilever body being attached at the first end, wherein
the sensor includes a diffraction grating whose quiescent diffraction characteristics change monotonically along the first
direction from the first end to the second end, and wherein the sensor is characterized by a second resonance frequency along
the second direction that is higher than the first resonance frequency;

a tip, the tip and the sensor being mechanically coupled at the second end; and
a light source that provides a first light signal to the sensor, wherein:
(a) the first light signal is incident on the sensor at a first position under a first set of conditions;
(b) the first light signal is incident on the sensor at a second position under a second set of conditions, wherein:
(i) the first and second positions are at different locations along the first direction between the first end and the second
end of the sensor;

(ii) the set of conditions includes a wavelength of the first light signal, an angle of incidence between the first light
signal and the sensor when the sensor is in its quiescent state, and a medium that is in contact with the surface; and

(iii) the first and second set of conditions vary from one another as to at least one condition within the set thereof.
US Pat. No. 9,243,232

INHIBITORS OF MITOCHONDRIAL FISSION AND METHODS OF USE THEREOF

The Board of Trustees of ...

1. A mitochondrial fission inhibitor peptide construct comprising a mitochondrial fission inhibitor peptide consisting of
7, 8 or 9 amino acids,
wherein the inhibitor peptide comprises the amino acid sequence as set forth in SEQ ID NO:12 having none, one, two or three
conservative amino acid substitutions; and

a carrier peptide selected from the group consisting of SEQ ID NOs: 31-45,
wherein the mitochondrial fission inhibitor peptide construct is no more than 62 amino acids in length.

US Pat. No. 9,344,162

EXPLOITING SPATIAL DEGREES OF FREEDOM IN MULTIPLE INPUT MULTIPLE OUTPUT (MIMO) RADIO SYSTEMS

The Board of Trustees of ...

1. A method comprising:
transmitting, by a secondary transmitter, a first learning signal, wherein the first learning signal causes an interference
to a primary transmitter communicating with a primary receiver;

receiving, at the secondary transmitter, a first characteristic value of the primary transmitter representative of the interference;
generating, based on the first characteristic value, a second learning signal, wherein the generated second learning signal
causes less interference to the primary transmitter communicating with the primary receiver, and wherein the less interference
is indicated by a received second characteristic value;

determining, based on at least the received first characteristic value and the received second characteristic value, a null-space
for a channel between the secondary transmitter and the primary receiver; and

transmitting, by the secondary transmitter, a signal in accordance with the determined null-space.

US Pat. No. 9,285,336

SENSING PLATFORM FOR QUANTUM TRANSDUCTION OF CHEMICAL INFORMATION

THE BOARD OF TRUSTEES OF ...

1. A system for sensing chemical information, the system comprising:
a fluidic system, comprising:
a sample acquisition zone;
a filtration module coupled to the sample acquisition zone;
an immunoseparation module coupled to the filtration module;
a tapered micro-chromatogram coupled to the immunoseparation module; and
an adsorption pad coupled to the tapered micro-chromatogram; and
a quantum tunneling biosensor interface coupled to the adsorption pad, the quantum tunneling biosensor interface comprising:
a transducing electrode array comprising dielectric thin films deposited on an electrode array; and
sensor interface circuitry coupled to the transducing electrode array.
US Pat. No. 9,249,200

EXPRESSION VECTOR COMPRISING A NUCLEOTIDE SEQUENCE ENCODING A VOLVOX CARTERI LIGHT-ACTIVATED ION CHANNEL PROTEIN (VCHR1) AND IMPLANTABLE DEVICE THEREOF

The Board of Trustees of ...

1. A recombinant expression vector comprising a nucleotide sequence encoding a Volvox carteri light-activated ion channel protein (VChR1).

US Pat. No. 9,170,312

PHASE-SENSITIVE IMAGING OF MAGNETIZATION EXCHANGE AND ISOTOPE FLUX

The Board of Trustees of ...

1. A method for imaging a substrate and product over time, comprising:
magnetically tagging the substrate and product with at least one magnetic gradient where magnetically tagging provides a tag-dependent
signal phase for the substrate and a different tag-dependent signal phase for the product;

providing at least one readout of magnetically tagged substrate and product over time; and
using tag-dependent signal phase to determine product that has been transformed from magnetically tagged substrate and substrate
that has been transformed from magnetically tagged product over time.

US Pat. No. 9,265,788

COMPOSITIONS AND METHODS FOR TREATMENT OF MITOCHONDRIAL DISEASES

The Board of Trustees of ...

1. A method of treating mitochondrial disease in a subject having a mitochondrial disease, comprising
administering a therapeutically effective amount of an inhibitor of a mitochondrial transport protein to the subject, wherein
the administering stabilizes or reduces an undesirable clinical symptom in the subject.

US Pat. No. 9,265,845

IMAGING METHODS USING ENGINEERED INTEGRIN BINDING PEPTIDES

The Board of Trustees of ...

1. A method of imaging a tissue highly expressing an endothelial integrin that is at least one of ?v?5 integrin, ?v?3 integrin
and ?5?1 integrin, comprising contacting said tissue with an integrin binding peptide, said integrin binding peptide comprising:
(a) a binding sequence specific to bind to at least one of ?v?5 integrin, ?v?3 integrin and ?5?1 integrin, said binding sequence
further being 11 amino acids long and comprising the sequence RGD; and

(b) a knottin scaffold substantially identical to EETI-II except that a portion of the knottin scaffold is replaced with the
binding sequence, said integrin binding peptide further having at least 90% identity to a peptide that is one of SEQ ID NO:
23 through SEQ ID NO: 52, inclusive, comprising cysteine disulfide linkages adjacent to the binding sequences,

said integrin binding peptide further comprising a label that can be detected when the integrin binding peptide is bound to
the tissue, thereby imaging the tissue.

US Pat. No. 9,246,106

ELECTRON DEFICIENT MOLECULES AND THEIR USE IN ORGANIC ELECTRONIC APPLICATIONS

The Board of Trustees of ...

1. An organic photovoltaic cell including an electron acceptor material, wherein the electron acceptor material comprises
molecules including one or more moieties selected from the group consisting of: vinylimide, vinylthioimide, alkynylimide and/or
alkynylthioimide moieties;
wherein the molecules have an electron acceptor group B and one to six electron acceptor A groups covalently bound to a B
group, wherein each of the A groups individually consists of:

a single XYZ structure, wherein X and Y are connected by two single covalent bonds, wherein Y and Z are connected by a single
covalent bond, and wherein Y has no bonds other than the two single covalent bonds to X and the single covalent bond to Z;

a) wherein X consists of a

 fragment,wherein W are each independently O or S, and wherein R is a C1-C20 branched, unbranched or cyclic alkyl or heteroalkyl group having none, some or all hydrogen atoms substituted with fluorine
atoms;
b) wherein Y consists of one or more aromatic rings; and
c) wherein Z is a doubly bonded hydrocarbon having a —C?C— structure or a triply bonded —C?C— structure.

US Pat. No. 9,415,138

DYNAMIC MACROPORE FORMATION USING MULTIPLE POROGENS

The Board of Trustees of ...

1. A method for making a macroporous 3-D tissue engineering scaffold from an article comprising multiple distinct macroparticulate
porogens and living cells distributed within a polymer scaffold, wherein the porogens are selectively and sequentially dissolvable
by corresponding distinct biocompatible stimuli, comprising: sequentially contacting the article with said distinct biocompatible
stimuli, wherein each of the porogens is selectively and sequentially dissolved by the corresponding biocompatible stimulus,
thereby temporally and spatially controllably forming macropores within the polymer scaffold, wherein the tissue engineering
scaffold is formed.

US Pat. No. 9,234,790

APPARATUS AND METHODS UTILIZING OPTICAL SENSORS OPERATING IN THE REFLECTION MODE

The Board of Trustees of ...

1. An optical apparatus comprising:
at least one optical bus configured to be optically coupled to at least one source of input optical signals, configured to
be optically coupled to at least one optical detector, and configured to be optically coupled to a plurality of reflective
sensing elements, wherein the at least one optical bus transmits an input optical signal from the at least one source to the
plurality of reflective sensing elements such that at least one reflective sensing element of the plurality of reflective
sensing elements receives a portion of the input optical signal and reflects at least a portion of the received portion, wherein
the at least one optical bus transmits the reflected portion to the at least one optical detector, wherein the at least one
optical bus comprises a distribution bus and a return bus, the distribution bus configured to be optically coupled to the
at least one source, the distribution bus comprising at least two distribution optical couplers each splitting the input optical
signal into a portion transmitted along the distribution bus and a portion transmitted to at least one reflective sensing
element of the plurality of reflective sensing elements, the return bus configured to be optically coupled to the at least
one optical detector, the return bus comprising at least two return optical couplers that each transmit the reflected portions
from multiple reflective sensing elements of the plurality of reflective sensing elements, and wherein at least one reflective
sensing element of the plurality of reflective sensing elements is optically coupled to the distribution bus by at least one
distribution optical coupler and to the return bus by at least the one distribution optical coupler or is optically coupled
to the return bus by at least one return optical coupler and to the distribution bus by at least the one return optical coupler.

US Pat. No. 9,184,099

BIOSENSOR DEVICES, SYSTEMS AND METHODS THEREFOR

The Board of Trustees of ...

1. An apparatus for sensing target materials including biological or chemical molecules in a fluid, the apparatus comprising:
a semiconductor-on-insulator (SOI) structure including an electrically-insulating layer;
a fluidic channel supported by the SOI structure and configured and arranged to receive and pass a fluid including the target
materials;

at least two electrodes configured and arranged to pass current for facilitating electrophoretic flow or electroosmotic flow
of the fluid through the fluidic channel;

a semiconductor device including at least three electrically-contiguous semiconductor regions doped to exhibit a common polarity
and located in the fluidic channel,

the semiconductor regions including a sandwiched region sandwiched between two of the other semiconductor regions, and configured
and arranged adjacent to the fluidic channel with a surface directed toward the fluidic channel for coupling to the target
materials in the fluidic channel, and further arranged for responding to a change in potential;

said two of the other semiconductor regions being configured and arranged at least partially on the electrically-insulating
layer, being doped at a higher concentration than the sandwiched region and being electrically connected to end electrodes,
wherein in response to the potential resulting from the target materials in the fluidic channel, said at least one contiguous
semiconductor region is configured and arranged to sense the presence of the target materials in the fluidic channel in response
to the flow of electrons in a conducting mode from one end electrode to another end electrode; and

an amplification circuit supported by the SOI structure and configured and arranged to facilitate sensing the target material
near or in the fluidic channel.

US Pat. No. 9,099,271

METHOD AND SYSTEM FOR OPERATING ELECTRON GUNS IN MAGNETIC FIELDS

The Board of Trustees of ...

1. A method of configuring an electron gun for generating and injecting an electron beam into a linac accelerating waveguide
operating in magnetic fringe fields of an MRI scanner in the absence of a magnetic shield, comprising:
a) providing an in-line MRI-linac configuration with no magnetic shielding;
b) determining an anode drift tube diameter at an injection point of a linac of said in-line MRI-linac configuration, using
an appropriately programmed computer, wherein said anode drift tube diameter is according to a value of a magnetic field from
an MRI scanner of said in-line MRI-linac configuration and according to a predetermined current density, wherein said magnetic
field comprises an isocenter, wherein twiss parameters are used by said appropriately programmed computer to determine a length
of said anode drift tube, wherein said twiss parameters are according to axial position and capture efficiency of said linac;

c) determining a transverse diameter of a Type M cathode in an electron gun, using said appropriately programmed computer,
wherein said transverse diameter of said cathode is according to said anode drift tube diameter and said current density;
and

d) minimizing a value of emittance in an electron beam of said electron gun at an entry point of said anode drift tube, using
said appropriately programmed computer, wherein said minimization comprises optimizing the distance between said cathode and
said anode, wherein said electron beam is directed proximal to an axis of symmetry of said MRI magnetic field, wherein an
electron gun is configured for generating and injecting an electron beam into a linac accelerating waveguide operating in
magnetic fringe fields of said MRI scanner in the absence of said magnetic shield.

US Pat. No. 9,381,276

ELECTROCHEMICAL DISINFECTION OF IMPLANTED CATHETERS

SRI INTERNATIONAL, Menlo...

1. An implantable catheter that can be electrochemically disinfected by creating a biofilm-inhibiting concentration of oxidizing
agents without removal from the body of a patient, the catheter comprising:
an elongate catheter body comprising a dielectric material and having a proximal region, a distal region, a lumen extending
through the catheter body and adapted to transport fluid from the proximal region to the distal region, an outer surface on
the exterior of the catheter body, and an inner surface on the interior of the lumen, and

at least two exterior electrodes on and integral with the outer surface of the catheter, the exterior electrodes being elongate
and extending longitudinally along the outer surface of the catheter body from the proximal region to the distal region, wherein
the exterior electrodes extend radially inward from the outer surface through a wall of the catheter body to the inner surface,
thereby additionally serving as interior electrodes;

wherein the two exterior electrodes are separated by a pair of gaps, each gap comprising the dielectric material of the catheter
body, and extending radially from the outer surface to the inner surface of the catheter body and longitudinally from the
proximal region to the distal region;

wherein the catheter is configured to be disinfected when, implanted in the patient's body, without removing the catheter
from the patient's body, and in the absence of an added biocidal agent, a voltage is applied across the exterior electrodes
of a magnitude that is effective to create a biofilm-inhibiting concentration of oxidizing agents from endogenous compounds
present in the body.

US Pat. No. 9,125,385

SITE-DIRECTED INTEGRATION OF TRANSGENES IN MAMMALS

The Board of Trustees of ...

1. A method of inserting a polynucleotide sequence into a genome of a murine cell, comprising:
introducing a circular nucleic acid into said murine cell,
wherein said circular nucleic acid comprises said polynucleotide sequence and a first unidirectional recombination site, and
wherein said genome of said murine cell comprises a second unidirectional recombination site at the intergenic Hipp11 (H11)
locus on mouse chromosome 11;

introducing an mRNA a nucleic acid encoding a site-specific, unidirectional recombinase into said cell; and
maintaining said cell under conditions that facilitate recombination between said first and second unidirectional recombination
sites mediated by said unidirectional recombinase, wherein said method results in a site-specific integration of said polynucleotide
sequence into the genome of said murine cell.

US Pat. No. 9,340,589

LIGHT-ACTIVATED CHIMERIC OPSINS AND METHODS OF USING THE SAME

The Board of Trustees of ...

1. A mammalian cell comprising a polynucleotide comprising a nucleotide sequence encoding a light-responsive chimeric polypeptide
comprising an amino acid sequence having at least 95% amino acid sequence identity to the amino acid sequence set forth in
SEQ ID NO:1, wherein the light-responsive chimeric polypeptide is present in the cell membrane.
US Pat. No. 9,283,289

SELF-QUENCHING ACTIVATABLE COX-2-SPECIFIC MULTI-MODAL MOLECULAR PROBES FOR DIAGNOSIS OF CANCERS, INFLAMMATION, AND IMMUNE SYSTEM DISORDERS

THE BOARD OF TRUSTEES OF ...

1. A composition comprising an activatable probe for the detection of a cell or tissue having cyclooxygenase-2 (COX-2) activity,
said activatable probe comprising:
(i) a fluorescent moiety consisting of indomethacin conjugated to 5-Rox-D (Fluorocoxib); and
(ii) a fluorescence quencher, wherein the fluorescent quencher is GHK-Cu+, wherein the fluorescent moiety and the fluorescence quencher are connected by a cleavable linker comprising a cleavable
peptide bond, wherein the linker is GHK, wherein the activatable probe is encapsulated in a liposome comprising sulfasalazine.

US Pat. No. 9,187,745

SYSTEM FOR OPTICAL STIMULATION OF TARGET CELLS

The Board of Trustees of ...

1. A method of inducing hyperpolarization of a mammalian cell expressing a light-driven chloride ion pump from Natronobacterium pharaonis (NpHR), the method comprising exposing the mammalian cell to yellow light to activate the expressed NpHR ion pump.

US Pat. No. 9,242,273

METHOD FOR OPERATING CMUTS UNDER HIGH AND VARYING PRESSURE

The Board of Trustees of ...

1. A capacitive micromachined ultrasonic transducer (CMUT) comprising:
a substrate;
a CMUT plate disposed above the substrate, wherein a sealed cavity between the substrate and the CMUT plate is substantially
evacuated;

wherein the CMUT is configured to operate at an external gas pressure of about 1 atmosphere or more;
wherein the CMUT plate makes partial contact with the substrate when no external bias voltage is applied to the CMUT due to
the external gas pressure;

wherein a contact between the CMUT plate and the substrate is configured to have a contact radius that varies with applied
pressure;

wherein the CMUT is configured such that an active part of the CMUT plate vibrates at an operating frequency of the CMUT during
operation of the CMUT;

wherein at least one electrode of the CMUT is configured as an annulus surrounding a contact zone where the CMUT plate makes
contact with the substrate;

wherein the annulus surrounds an electrically floating region of the CMUT, whereby an electric field in the contact zone is
decreased.

US Pat. No. 9,830,555

COMPUTATION USING A NETWORK OF OPTICAL PARAMETRIC OSCILLATORS

The Board of Trustees of ...

1. A computational machine, comprising:
an optical device configured to receive energy from an optical energy source and generate a number N1 of optical signals, N1 is 2 or greater; and

a number N2 of coupling devices, each of which controllably couples a plurality of the number N1 of optical signals, N2 is 1 or greater;

wherein the coupling devices are individually controlled to simulate a computational problem.

US Pat. No. 9,347,826

SYSTEM AND METHOD FOR MEASURING PERTURBATIONS UTILIZING AN OPTICAL FILTER AND A NARROWBAND OPTICAL SOURCE

The Board of Trustees of ...

1. An optical device comprising:
an optical filter having a power transmission spectrum as a function of wavelength and a group delay spectrum as a function
of wavelength, the power transmission spectrum comprising a plurality of peaks each comprising a local maximum and two non-zero-slope
regions with the local maximum therebetween, the optical filter having a wavelength-dependent figure of merit proportional
to a product of the group delay spectrum and the power transmission spectrum; and

a narrowband optical source in optical communication with the optical filter such that a transmitted portion of light from
the narrowband optical source is transmitted through the optical filter, the light from the narrowband optical source having
a wavelength at a non-zero-slope region of a peak of the plurality of peaks at which the figure of merit evaluated at the
local maximum of the peak is greater than the figures of merit evaluated at the local maxima of the other peaks of the plurality
of peaks.

US Pat. No. 9,398,935

ROBOTIC IMAGING SYSTEM

The Board of Trustees of ...

1. A robotic imaging system comprising:
a first robotic imaging arm including:
(a) a first robotic arm having two rotational degrees of freedom; and
(b) a first free-space optical subsystem disposed in the first robotic arm, wherein the first free-space optical subsystem
is configured to convey a first light signal through the first robotic arm to a first optical end effector at a distal end
thereof, and wherein elements of the first free-space optical system maintain polarization of the first light signal while
being conveyed through the first robotic arm.

US Pat. No. 9,301,980

ENHANCEMENT OF OSTEOGENIC POTENTIAL OF BONE GRAFTS

THE BOARD OF TRUSTEES OF ...

1. A composition of isolated enhanced human bone graft material comprising enhanced cells wherein the enhanced cells have
an increased level of expression for one or more biomarkers comprising Runx2, Osterix, Osteocalcin, alkaline phosphatase,
Axin2, Lef1, or Tcf4 after exposure ex vivo with a liposome comprising a Wnt protein, wherein the increased level of expression
for the one or more biomarkers is relative to equivalent cells from isolated human bone graft material unexposed to a liposome
comprising a Wnt protein, and wherein the isolated enhanced human bone graft material is obtained from a human subject at
least 50 years of age or older.

US Pat. No. 9,147,845

SINGLE WALLED CARBON NANOTUBE-BASED PLANAR PHOTODECTOR

SAMSUNG ELECTRONICS CO., ...

1. A single-walled carbon nanotube-based planar photodetector comprising:
a substrate;
a self assembled monolayer (SAM) on the substrate in a form of a plurality of lines;
a first electrode and a second electrode disposed on the substrate and spaced apart from each other;
a plurality of single-walled carbon nanotubes, each of the plurality of single-walled carbon nanotubes contacting the first
electrode and the second electrode, and the plurality of single-walled carbon nanotubes being aligned to closely contact a
surface of the SAM; and

an adsorbent attached to a surface of at least one of the plurality of single-walled carbon nanotubes, wherein when irradiated
with light, the adsorbent adsorbs either electrons or holes and p-dopes or n-dopes the at least one of the plurality of single-walled
carbon nanotubes, and when not irradiated with light, the at least one of the plurality of single-walled carbon nanotubes
is not p-doped or n-doped.

US Pat. No. 9,255,255

SYNTHESIS OF LINEAR AND BRANCHED POLYMERS OF POLYPEPTIDES THROUGH DIRECT CONJUGATION

THE BOARD OF TRUSTEES OF ...

1. A method for synthesis of a multimeric structure, the method comprising:
reacting in a bioorthogonal reaction:
two polypeptide subunit monomers, each comprising two first non-natural amino acids with two second subunit monomers, each
comprising two second nonnatural amino acids; and

coupling covalently, the two first subunits with the two second subunits by forming covalent linkages between the first and
second nonnatural amino acids, thereby synthesizing a multimeric structure.

US Pat. No. 9,480,715

METHOD TO INDUCE AND EXPAND THERAPEUTIC ALLOANTIGEN-SPECIFIC HUMAN REGULATORY T CELLS IN LARGE-SCALE

VERSITECH LIMITED, Hong ...

1. A method for inhibiting graft versus host diseases (GVHD) with alloantigen specific regulatory T cells, the method comprising:
generating the alloantigen specific regulatory T cells by contacting CD40-activated B cells from a donor of a allograft with
naive CD4+CD25? T cells from a patient receiving the allograft; and

administering the alloantigen specific regulatory T cells to the patient; wherein
the contacting of donor CD40-activated B cells with patient naïve CD4+CD25? T cells is conducted in an absence of exogenenous cytokines.

US Pat. No. 9,471,870

BRAIN-MACHINE INTERFACE UTILIZING INTERVENTIONS TO EMPHASIZE ASPECTS OF NEURAL VARIANCE AND DECODE SPEED AND ANGLE USING A KINEMATICS FEEDBACK FILTER THAT APPLIES A COVARIANCE MATRIX

The Board of Trustees of ...

1. An artificial controller of a prosthetic device, comprising:
(a) a brain machine interface having an algorithm executable by a computer, wherein the brain machine interface comprises
a mapping from neural signals to corresponding intention estimating kinematics of a limb trajectory, wherein the intention
estimating kinematics comprises speeds and angles;

b) the brain machine interface controlling the prosthetic device using recorded neural signals as input to the brain machine
interface and the mapping of the brain machine interface determining the intention estimating kinematics to control the prosthetic
device, wherein the controller results in an executed movement of the prosthetic device;

(c) a modified brain machine interface having an algorithm executable by the computer for modifying during the control of
the prosthetic device, at discrete time intervals over the course of the executed movement of the prosthetic device, the angles
in the brain machine interface, wherein each of the modifications of the angles comprises changes in the direction of the
angles towards an end target of the executed movement of the prosthetic device;

(d) the modified brain machine interface controlling the prosthetic device; and
(e) a kinematics feedback filter executable by the computer in both the brain machine interface and the modified brain machine
interface, wherein the kinematics feedback filter applies a covariance matrix of an a posteriori estimate of the intention
estimating kinematics at each time step of the discrete time intervals, whereby the kinematics are modeled as feedback from
the interfaces to a user of the prosthetic device.

US Pat. No. 9,393,005

SYSTEMS FOR THE PREVENTION OF SURGICAL SITE INFECTIONS

The Board of Trustees of ...

1. A surgical access system adapted to facilitate access to a surgical site within a body of a patient through an incision
in the body, the surgical access system comprising:
a first retention member;
a second retention member coupled to the first retention member by a connector, wherein the first retention member and the
second retention member are configured to expand the incision to provide access to the surgical site, wherein the connector
comprises two or more fluidically independent chambers, wherein at least a first chamber is configured to allow the application
of suction;

a fluid delivery member fluidly coupled to the connector;
a first group of perforations in a second chamber of the connector, wherein the first group of perforations is in fluid communication
with the fluid delivery member to allow a fluid to irrigate the surgical site; and

a second group of perforations in the first chamber of the connector which allow the fluid to be removed from the surgical
site after the fluid has irrigated the surgical site.

US Pat. No. 9,079,940

LIGHT-SENSITIVE ION-PASSING MOLECULES

The Board of Trustees of ...

1. An animal cell comprising a light-activated protein expressed on the cell membrane, wherein the protein comprises, in order
from amino terminus (N-terminus) to carboxyl terminus (C-terminus):
a) a core amino acid sequence at least 95% identical to the sequence shown in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, or SEQ
ID NO:4;

b) an endoplasmic reticulum (ER) export signal; and
c) a membrane trafficking signal.

US Pat. No. 9,442,087

ORGANIC THIN-FILM TRANSISTOR SENSOR ARRANGEMENTS

The Board of Trustees of ...

1. A method comprising:
providing an organic transistor including a gate and including a source, a drain, and an organic semiconducting channel therebetween
and with exposed portions of each of the source, drain and channel for permitting direct interaction between each of the source,
drain and channel with an aqueous solution;

presenting the aqueous solution to the exposed portions;
presenting a low voltage to the gate; and
sensing, in response to the steps of presenting and to direct chemical interaction between the aqueous solution and the channel
while the aqueous solution is also in direct contact with both the source and drain, characteristics of the aqueous solution
based on the direct chemical interaction between the aqueous solution and the channel.

US Pat. No. 9,373,088

BRAIN MACHINE INTERFACE UTILIZING A DISCRETE ACTION STATE DECODER IN PARALLEL WITH A CONTINUOUS DECODER FOR A NEURAL PROSTHETIC DEVICE

The Board of Trustees of ...

1. Method of controlling a prosthetic device, comprising:
a brain machine interface for controlling said prosthetic device based on neural brain signals, wherein said brain machine
interface in said control executes in parallel a continuous decoder and a discrete action state decoder,

wherein said continuous decoder controls kinematics of said prosthetic device based on said neural brain signals as input
to said continuous decoder,

wherein for said discrete action state decoder the neural brain signals are initially projected into a neural space of lower
dimensionality compared to the dimensionality of the neural brain signals,

wherein said discrete action state decoder controls discrete action states of said prosthetic device based on said projected
neural brain signals as input to said discrete action state decoder, wherein said discrete action states comprise:

(i) discrete velocity states of said prosthetic device,
(ii) discrete idle states; and
(iii) discrete task states of said prosthetic device,
wherein said discrete action state decoder is based on learning models, wherein said learning comprises:
(j) learning distribution models of neural data for each of said states (i), (ii) and (iii); and
(jj) learning probability transition models between said states (i), (ii) and (iii) wherein the likelihood of said discrete
action states is decoded and propagated through time.

US Pat. No. 9,109,255

METHODS AND COMPOSITIONS FOR DETERMINING RESPONSIVENESS TO ANTIBODY THERAPY

The Board of Trustees of ...

1. A method of treating a human subject suffering from non-Hodgkin's lymphoma (NHL) comprising:
(a) obtaining a nucleic acid sample from the subject;
(b) detecting in said nucleic acid the presence of a Fc?RIIa H/H genotype;
(c) correlating the presence of said Fc?RIIa H/H genotype with an increased likelihood of responsiveness to IgG anti-CD20
antibody treatment; and

(d) treating said subject with administration of an IgG anti-CD20 antibody.
US Pat. No. 9,101,658

IMMUNE EFFECTOR CELLS PRE-INFECTED WITH ONCOLYTIC VIRUS

THE BOARD OF TRUSTEES OF ...

1. A method of treating cancer in a patient, the method comprising:
administering systemically to a cancer patient at least 108 of human cytokine induced killer (CIK) cells infected with a oncolytic vaccinia virus in an extended eclipse phase, wherein
the oncolytic vaccinia virus:

(i) is replication competent, and
(ii) comprises a genetic modification that substantially eliminates viral thymidine kinase (TK) and a genetic modification
that substantially eliminates active viral growth factor (VGF);

wherein tumor cells of the cancer are reduced or eliminated.

US Pat. No. 9,086,098

ANTI-TWIST JOINT, ORIENTING SYSTEM AND METHOD

The Board of Trustees of ...

1. An anti-twist joint comprising:
a base;
a rotating member rotatably mounted to the base such that the rotating member rotates about a first axis;
a pivoting member pivotably mounted to the rotating member such that the pivoting member pivots about a second axis;
an anti-twist member rotatably mounted to the pivoting member;
a coupling apparatus having one or more features on the anti-twist member that contact one or more features on the base to
rotationally couple the anti-twist member to the base such that the rotational orientation of the anti-twist member relative
to the base remains constant regardless of a rotational orientation or a pivoting orientation of the pivoting member relative
to the base; and

a pivot actuator coupled between the pivoting member and the rotating member to control a pivot angle therebetween.

US Pat. No. 9,255,335

CATALYSTS FOR LOW TEMPERATURE ELECTROLYTIC CO2 REDUCTION

The Board of Trustees of ...

1. A method for electrochemically reducing CO2 comprising:
providing a cathode, wherein the cathode comprises a conductive substrate with a catalyst of a metal and a metal oxide based
coating on a side of the cathode, wherein the providing the cathode comprises:

providing a conductive substrate with a metal coating;
providing on the conductive substrate a metal oxide coating by either annealing the metal coating, electrochemically oxidizing
the metal coating, chemically oxidizing the metal coating, or depositing a metal oxide layer; and

reducing metal oxide in the metal and metal oxide based coating to the metal 0 oxidation state;
providing an anode spaced apart from the cathode;
providing an ionic transport between the anode and cathode;
exposing the cathode to CO2 and H2O
exposing the anode to H2O;
providing a voltage between the cathode and anode; and
reducing CO2 to CO and/or HCO2H.

US Pat. No. 9,195,043

MICROSCOPY IMAGING DEVICE WITH ADVANCED IMAGING PROPERTIES

The Board of Trustees of ...

1. An epifluorescence microscope comprising:
an image capture circuit including an array of optical sensors; and
an optical arrangement configured (i) to direct excitation light of less than about 1 mW over an area that is at least 0.5
mm2 encompassed within a field of view which comprises a target object, and (ii) to direct epi-fluorescence emission caused by
the excitation light to the array of optical sensors, the optical arrangement and array of optical sensors each being sufficiently
close to the target object to provide at least 2.5 ?m resolution for an image of the field of view.

US Pat. No. 9,138,965

CONDUCTIVE FIBROUS MATERIALS

The Board of Trustees of ...

1. An electronic device comprising:
a fibrous planar material including a plurality of fibers coated by a conductive coating of carbon nanotubes on respective
surfaces of the plurality of fibers and forming a matrix of conductive-coated fibers and including electrolyte molecules that
occupy openings between the conductive-coated fibers and that have a cross-section that is less than a size of the openings;

a coating of metal nanowires on the coating of carbon nanotubes; and
conductive materials embedded in the fibrous planar material and between the plurality of fibers.

US Pat. No. 9,092,467

SYSTEMS AND METHODS FOR DISPLAYING DATA IN SPLIT DIMENSION LEVELS

The Board of Trustees of ...

1. A method for visualizing a multidimensional dataset, comprising:
at a computing device having one or more processors and memory storing one or more programs configured for execution by the
one or more processors:

identifying a dimensional hierarchy associated with the multidimensional dataset, wherein the dimensional hierarchy includes
at least a first dimension and a sub-dimension of the first dimension;

displaying a graphical user interface window that includes a schema display region and a data visualization region that is
distinct from the schema display region, wherein the schema display region includes a display of metadata for the plurality
of dimensions and measures, including the first dimension and the sub-dimension;

detecting user requests to associate the metadata identifying the first dimension with a first axis shelf in the data visualization
region and to associate the metadata identifying the sub-dimension with a second axis shelf in the data visualization region;

in response to the user requests,
generating a plurality of panes for a visual table in the data visualization region, wherein each pane has a first axis corresponding
to the first dimension associated with the first axis shelf and a second axis corresponding to the sub-dimension associated
with the second axis shelf, and wherein the second axis is in a different direction from the first axis; and

populating each pane in the visual table with a plurality of displayed marks, wherein each displayed mark corresponds to a
respective tuple in the multidimensional dataset.

US Pat. No. 9,211,146

SYSTEMS AND METHODS FOR POSTERIOR DYNAMIC STABILIZATION OF THE SPINE

The Board of Trustees of ...

1. An interspinous device for stabilizing at least one spinal motion segment of a subject comprising a first vertebra having
a first spinous process and a second vertebra having a second spinous process, the device comprising:
an expandable member having an unexpanded configuration and an expanded configuration, wherein the expandable member in the
unexpanded configuration has a size configured for delivery through a cannula and positioning between the first and second
spinous process and in the expanded configuration provides distraction of the first and second spinous processes, wherein
the expandable member includes

a first concave engagement portion,
a second concave engagement portion,
a hub,
at least one strut rotatably coupled to the hub, and
a central element positioned between the first and second concave engagement portions, wherein the central element is axially
movable relative to the hub to cause the at least one strut to rotate relative to the hub to move the first and second concave
engagement portions outwardly while the hub and the at least one strut are positioned with the subject and positioned directly
posterior to the subject's spinal motion segment and also while the central element is positioned directly between the first
and second spinous processes to mechanically actuate the expandable member from the unexpanded configuration to the expanded
configuration such that the first spinous process is held by the first concave engagement portion and the second spinous process
is held by the second concave engagement portion.

US Pat. No. 9,205,260

METHODS FOR STIMULATING A DORSAL ROOT GANGLION

The Board of Trustees of ...

1. A method of pharmacologically modulating a dorsal root ganglion comprising:
implanting an elongate body into an epidural space, wherein the elongate body has a conduit for delivery of a pharmacological
agent;

advancing the elongate body along a nerve root and positioning an outlet of the conduit near the dorsal root ganglion associated
with the nerve root; and

delivering a pharmacological agent from an implanted delivery device through the conduit so that the pharmacological agent
pharmacologically modulates the dorsal root ganglion without pharmacologically modulating an associated ventral root, wherein
the implanted delivery device comprises a reservoir for storing the pharmacological agent and a pump for moving the pharmacological
agent from the reservoir to the conduit.

US Pat. No. 9,192,627

TUMOR VACCINATION IN COMBINATION WITH HEMATOPOIETIC CELL TRANSPLANTATION FOR CANCER THERAPY

The Board of Trustees of ...

1. A method for preparing a therapeutic cell composition for treating cancer of a subject, the method comprising:
(a) obtaining tumor cells from the subject;
(b) vaccinating a donor with a composition comprising;
(i) tumor cells obtained from the subject and
(ii) an adjuvant;
(c) mobilizing a set of immune and hematopoietic cells in the donor;
(d) collecting the set of immune and hematopoietic cells from the donor; and
(e) enriching CD34+ cells and T cells from the set of immune and hematopoietic cells;wherein the subject and the donor are different.

US Pat. No. 9,184,319

MULTI-TERMINAL MULTI-JUNCTION PHOTOVOLTAIC CELLS

The Board of Trustees of ...

1. A method of forming transparent electrodes on organic photovoltaic cells, the method comprising:
forming a layer of dissolvable material on a substrate;
depositing conductive nanowires suspended in a solution on the layer of dissolvable material;
evaporating the solution to form a nanowire mesh;
heating the nanowire mesh to join junctions where nanowires cross in the nanowire mesh;
affixing the nanowire mesh on a layer of one or more organic photovoltaic cells; and
dissolving the layer of dissolvable material, the nanowire mesh forming a transparent electrode on the layer of one or more
organic photovoltaic cells.

US Pat. No. 9,175,079

DEPLETION OF TERATOMA-FORMING PLURIPOTENT STEM CELLS

THE BOARD OF TRUSTEES OF ...

1. A method of depleting teratoma-forming pluripotent stem cells from a mixed cell population comprising cells differentiated
from the pluripotent stem cells, the method comprising:
contacting a mixed population of cells suspected of comprising pluripotent stem cells with an antibody that specifically binds
an H type-1 antigen epitope recognized by monoclonal antibody 8e11; and

depleting from said population those cells that bind to the antibody, to provide a differentiated cell population depleted
of teratoma-forming pluripotent stem cells.

US Pat. No. 9,150,882

SELF-COMPLEMENTARY PARVOVIRAL VECTORS, AND METHODS FOR MAKING AND USING THE SAME

The Board of Trustees of ...

1. A parvovirus vector template nucleic acid for creating a self-complementary, genetically stable, infectious recombinant,
adeno-associated virus
(rAAV) virion comprising:
a) a 5? inverted terminal repeat (ITR);
b) a 3? ITR; and
c) a foreign DNA insert comprising one or more expression cassettes, each independently ranging in size from about 0.2 kb
to about 2.2 kb, and adding up to a total size of no more than 2.4 kb in length between the 5?ITR and the 3? ITR;

wherein (i) the 5? and the 3? ITR have between 50 and 80% complementarity to each other, (ii) the 3? ITR serves as a primer
for DNA replication, (iii) the 5? or 3? ITR is from AAV-2 and the other ITR is from AAV-4, and (iv) at least one of the 5?
or 3? ITRs does not contain a functional terminal resolution site (trs).

US Pat. No. 9,100,557

VARIABLE IMAGING ARRANGEMENTS AND METHODS THEREFOR

THE BOARD OF TRUSTEES OF ...

1. A digital imaging system for capturing data usable for synthesizing an image of a scene, the system comprising:
a main lens positioned to receive light from a scene to be digitally captured;
a light ray sensor for sensing light from the scene as light rays of a light field, the light ray sensor comprising,
a microlens array comprising a plurality of microlenses and positioned to receive light from the scene through the main lens
and to capture microlens images beneath each of the plurality of microlenses; and

a photosensor array comprising a plurality of photosensors, wherein the photosensor array is positioned to receive light from
the microlens array, and in a first position is coincident with a focal plane of the microlens array such that the microlens
images are in focus;

an actuator configurable to set a distance between the photosensor array and the microlens array, wherein when the distance
is shorter than the distance of the first position, the microlens images become defocused, and wherein each level of defocus
provides a difference light field sampling pattern; and

a processor configurable to provide image data characterizing a synthesized image as a function of the light from the light
field sensed at different photosensors of the photosensor array.

US Pat. No. 9,057,053

DIRECT CONVERSION OF CELLS TO CELLS OF OTHER LINEAGES

The Board of Trustees of ...

1. A method of converting non-neuronal cells into induced neuronal/oligodendrocytes/astrocytes/neural stem cells (iNs), the
method comprising: contacting a population of non-neuronal somatic cells in vitro with a neuron reprogramming (NR) system
consisting of reprogramming factors Asci1, Brn2 and Myt1I for a period of time sufficient to reprogram said non-neural cells,
wherein a population of iNs is produced.
US Pat. No. 9,453,215

CELL LINE, SYSTEM AND METHOD FOR OPTICAL CONTROL OF SECONDARY MESSENGERS

The Board of Trustees of ...

1. A method for generating secondary messengers in a cell, the method comprising:
a) expressing in the cell a chimeric light-responsive fusion protein comprising a light-responsive rhodopsin-based membrane
protein and a heterologous alpha-1 adrenergic receptor, wherein said expression provides for production of a secondary messenger
in response to light, and wherein the chimeric light-responsive fusion protein comprises an amino acid sequence having at
least 85% amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO:4, wherein the cell expresses a secondary
messenger-targeted cation channel that is responsive to the secondary messenger; and

b) stimulating the chimeric light-responsive fusion protein with light, thereby generating the secondary messenger in the
cell.

US Pat. No. 9,399,068

HETERO-ASSEMBLING, TUNABLE, AND INJECTABLE HYDROGELS FOR CELL ENCAPSULATION

The Board of Trustees of ...

1. A viscoelastic hydrogel, comprising: a protein hetero-assembled with a polymer, wherein the protein cannot self-assemble
with itself, wherein the polymer cannot self-assemble with itself, wherein the protein includes a first association sequence
(1stA) and a first spacer (1stSp), wherein the polymer includes a second association sequence (2ndA) and a second spacer (2ndSp),
wherein the first association sequence and the second association sequence are physically cross-linked to interact with each
other with a 1:1 known and specific stoichiometry to form a three dimensional scaffold, wherein the protein is represented
by {1stA(1stSp)}x1stA, where x is ?2, and the polymer is represented by {2ndA(2ndSp)}y2ndA, where y?2.

US Pat. No. 9,335,466

WAVEGUIDE APPARATUSES AND METHODS

The Board of Trustees of ...

1. An optical fiber waveguide comprising:
a substrate having a first dielectric constant and that includes
a lattice that includes a plurality of lattice regions having a second, different dielectric constant;
a longitudinally-extending defect in the lattice that acts with trapped transverse modes including at least one of a magnetic
mode and an electric mode, the defect being configured and arranged to facilitate wave propagation along the longitudinal
direction while confining the wave transversely and in which a corresponding phase velocity equals the speed of light (TMSOL); and

a set of one or more deviations from the lattice configured and arranged to produce at least one of additional modes and coupling
options for the waveguide, the deviations having physical properties that are bounded by a figure of merit.

US Pat. No. 9,333,209

COMPOSITIONS FOR INCREASING HAIR GROWTH

The Board of Trustees of ...

1. A method for treating skin, scalp or hair comprising:
applying to skin, scalp or hair of an individual a composition comprising:
an effective dose of an agent to promote anagen phase of the hair cycle, where the agent is follistatin-like 1 protein; and
a cosmetically acceptable vehicle.

US Pat. No. 9,271,674

OPTOGENETIC MAGNETIC RESONANCE IMAGING

The Board of Trustees of ...

1. A method comprising:
modifying a target neural cell population in a first region of a brain to express a light-responsive opsin polypeptide;
stimulating, using a light pulse, the light-responsive opsin polypeptide in the target neural cell population;
scanning multiple regions of the brain via functional magnetic resonance imaging to observe a neural reaction in response
to the stimulation in at least one of the multiple regions of the brain and, in response, determine whether neural projections
in a second region of the brain are connected to at least some of the modified target cell population in the first region
of the brain.

US Pat. No. 9,265,413

I-DDROP: INTERFACIAL DEWETTING AND DRAINAGE OPTICAL PLATFORM

The Board of Trustees of ...

1. A system for analyzing characteristics of a contact lens, comprising:
(a) a Langmuir trough fixed onto a stationary support structure with heating elements, wherein the Langmuir trough allows
one to spread an insoluble monolayer of material on top of an aqueous sub-phase at a controlled surface pressure and temperature;

(b) a dome holder supporting a spherical titanium dome capable of supporting the contact lens;
(c) a moving platform for elevating the dome holder, while holding the contact lens on top of the spherical titanium dome,
from an initial position slightly beneath the interface of the content in the Langmuir trough and sending the contact lens
through the content in the Langmuir trough at computer-controlled speeds;

(d) an interferometer for acquiring thickness data of an aqueous layer on the top of the lens as a function of time;
(e) a color CCD camera for acquiring video data of the contact lens; and
(f) a computer executing a computer-implemented code for analyzing the acquired video data and outputting wettability characteristics
of the contact lens.

US Pat. No. 9,241,637

SYSTEMS AND METHODS FOR MONITORING THE CIRCULATORY SYSTEM

The Board of Trustees of ...

1. A method comprising:
generating an arterial stiffness measurement by
in a body scale including and integrating a first sensor, using the first sensor to capture, while a user is standing on the
body scale, a BCG (ballistocardiogram) or hand-to-hand impedance cardiogram T1 signal that is indicative of mechanical movement of blood through a user's aorta and that is indicative of a proximal cardiogram
timepoint or a T1 carotid timepoint;

using a second sensor to detect a pressure pulse at a location sufficiently distal to the user's aorta to allow a determination
of arterial pulse wave velocity; and

using logic circuitry to determine the arterial pulse wave velocity by calculating timings corresponding to the T1 signal and a timing of the pressure pulse.

US Pat. No. 9,228,931

IMAGING AND EVALUATING EMBRYOS, OOCYTES, AND STEM CELLS

The Board of Trustees of ...

1. A method for assessing human embryo developmental potential in vitro in an automated system comprising the steps of:
a) capturing periodic sequential images of a human embryo over a 1-5 day period of human embryo development using one or more
microscopes configured in an incubator that are operably linked to a computer comprising imaging software to capture the sequential
images; and

b) using image analysis software configured on the computer to determine a cellular activity parameter from the sequential
images of step a), wherein the cellular activity parameter comprises the timing interval between the first and second mitosis
of the human embryo and the timing interval between the second and third mitosis of the human embryo; and

c) using software configured on the computer to assess the developmental potential of the human embryo from the cellular activity
parameter of step b) wherein said image analysis software determines that an embryo has good developmental potential if the
time interval between the first and second mitosis is about 8 to about 15 hours and/or the interval between the second and
third mitosis is about 0 to about 30 minutes;

d) transferring an embryo determined in step c) to have good developmental potential to a recipient.
US Pat. No. 9,175,095

LIGHT-ACTIVATED CHIMERIC OPSINS AND METHODS OF USING THE SAME

The Board of Trustees of ...

1. An isolated light-responsive chimeric polypeptide comprising an amino acid sequence having at least 95% amino acid sequence
identity to the amino acid sequence set forth in SEQ ID NO:1.

US Pat. No. 9,165,694

NANOWIRE APPARATUSES AND METHODS

The Board of Trustees of ...

1. A method comprising:
providing a base layer;
providing a nanowire solution on the base layer resulting in a first layer of a plurality of nanowires disposed in a first
plane, and a second layer of a plurality of nanowires disposed in a second plane under the first plane; and

activating the nanowire solution using light-induced heat generation and therein creating recrystallization of nanowires in
the second layer into nanowires in the first layer at overlapping junctions of the nanowires in the first layer and the nanowires
in the second layer, wherein each of the overlapping junctions of the nanowires in the first layer and the second layer includes
material from a nanowire of the first layer of the plurality of nanowires being recrystallized into an overlapping nanowire
of the second layer of the plurality of nanowires.

US Pat. No. 9,085,536

ACONITINE COMPOUNDS, COMPOSITIONS, USES, AND PREPARATION THEREOF

The Board of Trustees of ...

1. A compound represented by structural formula (II):
or a pharmaceutically acceptable salt thereof, wherein:
R is alkyl, alkenyl, alkynyl, alkoxy, alkylamino, aryl, aryloxy, arylamino, aralkoxy, aralkamino, heteroaryl, heteroaryloxy,
heteroarylamino, heteroaralkyl, heteroaralkoxy, heteroaralkamino, cycloalky, cycloalkenyl, cycloalkoxy, cycloalkamino, heterocyclyl,
heterocyclyloxy, heterocyclylamino, heterocyclylalky, heterocyclylalkoxy, or heterocyclylalkamino, and is optionally substituted
with 1 to 3 A groups;

R2 is alkyl, alkoxy, or,


each R3 is independently hydrogen or a silyl protecting group;

each R4 is alkyl, alkenyl, alkynyl, alkoxy, alkylamino, aryl, aryloxy, arylamino, aralkoxy, aralkamino, heteroaryl, heteroaryloxy,
heteroarylamino, heteroaralkyl, heteroaralkoxy, heteroaralkamino, cycloalky, cycloalkenyl, cycloalkoxy, cycloalkamino, heterocyclyl,
heterocyclyloxy, heterocyclylamino, heterocyclylalky, heterocyclylalkoxy, or heterocyclylalkamino, and is optionally substituted
with 1 to 3 A groups;

each A is independently alkyl, alkenyl, alkynyl, alkoxy, alkanoyl, alkylamino, aryl, aryloxy, arylamino, aralkyl, aralkoxy,
aralkanoyl, aralkamino, heteroaryl, heteroaryloxy, heteroarylamino, heteroaralkyl, heteroaralkoxy, heteroaralkanoyl, heteroaralkamino,
cycloalkyl, cycloalkenyl, cycloalkoxy, cycloalkanoyl, cycloalkamino, heterocyclyl, heterocyclyloxy, heterocyclylamino, heterocyclylalky,
heterocyclylalkoxy, heterocyclylalkanoyl, heterocyclylalkamino, hydroxyl, thio, amino, alkanoylamino, aroylamino, aralkanoylamino,
alkylcarboxy, carbonate, carbamate, guanidinyl, urea, halo, trihalomethyl, cyano, nitro, phosphoryl, sufonyl, sulfonamindo,
or azido; and

R5 is alkyl;
provided that,when R is unsubstituted phenyl, R2 is
and each R3 is hydrogen, then R4 is not alkyl or alkenyl; and
when R is p-methoxyphenyl, R2 is

and each R3 is hydrogen, then R4 is not methyl.

US Pat. No. 9,747,633

METHOD AND RELATED APPARATUS FOR GENERATING ONLINE AND PRINTING ON-DEMAND COMPILATION OF WORKS WITH CUSTOMER SELECTABLE PRINTING OPTIONS

THE BOARD OF TRUSTEES OF ...

1. In a computer system comprising a server for customizing price-related options for printing a compilation of works and
at least one copyright management center server, a computer implemented method executed by the server comprising the steps
of:
(a) compiling the compilation of works;
(b) sending information regarding the works to the at least one copyright management center server for calculating prices
of the works;

(c) setting a plurality of different printing options that describe manners of printing the compilation of works, wherein
the different options correspond to different printing prices;

(d) displaying, in a first graphical user interface (GUI), a GUI input field corresponding to each of the plurality of options
which indicates whether or not the option is to be displayed to customers, including a GUI input field that indicates whether
or not a first option to print the compilation of work with color or black and white is to be displayed to customers, a GUI
input field that indicates whether or not a second option to print the compilation of work with different types of paper is
to be displayed to customers, and a GUI input field that indicates whether or not a third option to print the compilation
of work with different types of binding is to be displayed to customers;

(e) receiving, via the GUI input fields of the first GUI displayed in step (d), one or more inputs from a user which indicate
one or more of the first to third options are to be displayed to the customers and which indicate other one or more of the
first to third options are not to be displayed to the customers;

(f) displaying, in a second graphical user interface (GUI), each of the first to third options that have been indicated in
step (e) as to be displayed to customers, while hiding each of the first to third options that have been indicated in step
(e) as not to be displayed to customers;

(g) receiving from a customer, via the second GUI, inputs that select an option value for each of the first to third options
that are displayed in step (f); and

(h) providing the customer with a total price for printing the compilation of works based on the options that the customer
has selected in step (g) and the prices of the works.

US Pat. No. 9,648,713

HIGH-GAIN THOMPSON-SCATTERING X-RAY FREE-ELECTRON LASER BY TIME-SYNCHRONIC LATERALLY TILTED OPTICAL WAVE

The Board of Trustees of ...

1. Apparatus for producing X-rays, the apparatus comprising:
at least one source of optical radiation configured to emit pulses of optical radiation;
focusing optics configured to bring two counter-propagating pulses of the optical radiation to a common line focus;
an electron source configured to provide an electron beam aligned with the line focus;
wherein the focusing optics include one or more dispersive optical elements configured to introduce a tilt angle between phase
fronts of the counter-propagating pulses and pulse fronts of the counter-propagating pulses;

wherein the tilt angle is selected to substantially match a velocity of pulse front propagation along the line focus with
an electron velocity of the electron beam along the line focus; and

wherein a standing wave pattern formed by the counter-propagating pulses at the line focus acts as an undulator for emission
of X-rays by electrons in the electron beam.

US Pat. No. 9,562,087

HIGH AFFINITY PD-1 AGENTS AND METHODS OF USE

The Board of Trustees of ...

1. A high affinity programmed cell death 1 (PD-1) mimic polypeptide, comprising an amino acid sequence that is a variant of
a human wild-type PD-1 ectodomain sequence, wherein the high affinity PD-1 mimic polypeptide:
(a) lacks a wild-type PD-1 transmembrane domain,
(b) comprises an amino acid sequence having 85% or more sequence identity to the amino acid sequence set forth in any of SEQ
ID NOs: 2-25 and 39-46, and

(c) relative to the amino sequence set forth in SEQ ID NO: 2, comprises one or more amino acid changes that cause an increased
affinity for human and/or mouse programmed cell death 1 ligand 1 (PD-L1).

US Pat. No. 9,458,506

MARKERS FOR THE DETECTION OF HUMAN EMBRYO DEVELOPMENTAL QUALITY

The Board of Trustees of ...

1. A method for predicting blastocyst quality of a human embryo in vitro, the method comprising:
analyzing expression of one or more genes associated with epigenetic regulation of gene expression wherein the genes associated
with epigenetic regulation of gene expression are selected from ATF2, KAT5, MSK2, PRMT5, SETDB1, DNMT1 and AURKB;

comparing the expression to a control sample;
wherein altered expression levels are indicative of an greater potential for aneuploidy in the embryo, wherein an embryo or
population of embryos assessed as having a low quality are cultured in medium supplemented with one or more of BDNF, IGF-I,
estradiol, GDNF, leptin, FGF2, EGF, and GM-CSF.

US Pat. No. 9,387,082

HYDROGEL ARTHROPLASTY DEVICE

The Board of Trustees of ...

1. A cartilage replacement prosthesis having a first surface and a lubricious second surface, the prosthesis comprising a
covalently cross-linked polyacrylic acid network and a polyurethane network, the polyacrylic acid network forming a composition
gradient within the polyurethane network such that the polyacrylic acid content of the prosthesis is at a maximum at the second
surface and decreases with distance from the second surface towards the first surface, the prosthesis comprising polyurethane
at all distances from the second surface to the first surface, the prosthesis comprising water, wherein the water forms a
continuous hydration gradient within the polyacrylic acid network and the polyurethane network.
US Pat. No. 9,360,472

CELL LINE, SYSTEM AND METHOD FOR OPTICAL-BASED SCREENING OF ION-CHANNEL MODULATORS

The Board of Trustees of ...

1. A system for screening drug candidates to identify their effects on a cell membrane voltage-gated ion channel, the system
comprising:
a) a recombinant mammalian cell genetically modified to express a light responsive ChR2 ion channel comprising an amino acid
sequence having at least 75% amino acid sequence identity to SEQ ID NO:1 and a heterologous microbial light-responsive ion
pump, wherein the cell comprises a voltage-gated ion channel and a fluorescence producing voltage sensor;

b) a chemical delivery device for introducing the drug candidates to be screened;
c) an optical delivery device to activate the light responsive ion channel or ion pump;
d) an optical sensor to monitor fluorescence produced by the voltage sensor;
e) a processor to process data received from the optical sensor; and
f) memory for storing the data received from the optical sensor.

US Pat. No. 9,345,789

SPECIFIC INHIBITORS AND ACTIVE SITE PROBES FOR LEGUMAIN

The Board of Trustees of ...

1. A compound, having a formula according to either Formula I or Formula II below

wherein,
(a) R1 is either (i) linker-label, wherein linker is lower alkyl, lower alkyl-aryl, or aryl; and label is a radiolabel or
an optical label, said linker optionally comprising a cell penetrating peptide; or (ii) lower alkyl, lower alkyl-aryl, or
aryl without a label;

(b) P3 is a side chain of leucine or a non-natural amino-acid selected from the group consisting of (2-furyl)alanine, (2-thienyl)alanine,
4-pyridylAla, 1-amino-1-cyclohexane carboxylic acid, 1-amino-1-cyclopentane carboxylic acid, 2-Abz, 3-Abz-, 2-Abu, 3-amino-3-phenyl
propionic acid, dehydroAbu, ACPC, Aib, AllylGly, Amb, Amc, Bip, Bpa, Cba, Cha, deltaLeu, deltaVal, Hyp, Igl, Inp, 1-Nal, 2-Nal,
Nva, 4-nitroPhe, 4-MethylPhe, 4-Methyl-D Phe, Phe(pI), Phe-4-NH(Boc), hPhe, Phg, pip, Dpip, propargylglycine, Thz, Tic, Tle,
3-NitroTyr, Fmoc-L-neopentylglycine, Fmoc-pCl-L-Phe-OH, Fmoc-pBr-L-Phe-OH, Fmoc-4-amino-tetrahydropyran-4-carboxylic acid,
Fmoc-L-Hol, Fmoc-Pip(Boc)-OH, Fmoc-L-styrylalanine, Fmoc-L-homoCha, Fmoc-L-Dab(Boc)-OH, Fmoc-L-Dapa(Boc)-OH, Fmoc-4-[2-(Boc-amino)ethoxy]-L-phenylalanine,
and Fmoc-4-(tert-butoxycarbonylmethoxy)-L-phenylalanine;

(c) P2 is selected from the group consisting of (i) proline such that the compound of Formula I is

(ii) a side chain of leucine, and (iii) a side chain of a non-natural amino acid as defined for P3;
(d) W has the formula of a C double bonded to its adjacent CH group or an epoxide group wherein W is C and an epoxide oxygen
is bonded to it and an adjacent carbon; and

(e) R2 is selected from the group consisting of lower alkyl, aryl, and lower alkyl-aryl.
US Pat. No. 9,266,725

NANOTUBE STRUCTURES, METHODS OF MAKING NANOTUBE STRUCTURES, AND METHODS OF ACCESSING INTRACELLULAR SPACE

The Board of Trustees of ...

1. A nanotube device, comprising:
a porous structure having a pore diameter of between 100-750 nm and a plurality of nanotubes extending through the porous
structure, wherein the nanotubes extend a distance above the porous structure and are hollow to allow material to pass through
the nanotubes and have an outer diameter of between 100-750 nm wherein the nanotubes of the porous structure are in fluidic
communication with a fluidic passage of a device on a side opposite the nanotubes extending from a surface of the porous structure;

further wherein a density of the nanotubes is between about 106 and 108 nanotubes/cm2.

US Pat. No. 9,242,274

PRE-CHARGED CMUTS FOR ZERO-EXTERNAL-BIAS OPERATION

The Board of Trustees of ...

1. A capacitive micromachined ultrasonic transducer (CMUT) comprising:
a substrate;
a CMUT plate disposed above the substrate;
a substrate electrode disposed on the substrate;
a plate electrode disposed on the CMUT plate;
a floating electrode disposed either on the substrate or on the CMUT plate, wherein the floating electrode has no electrical
connection to the substrate electrode or to the plate electrode; and

wherein an electrical DC bias of the CMUT is provided in part or in full by charges trapped on the floating electrode;
wherein the CMUT is configured as a transducer relating an electrical capacitance formed by the substrate electrode and the
plate electrode to an acoustic deformation of the CMUT plate.

US Pat. No. 9,193,997

MEASURING AND MONITORING OF CELL CLONALITY

The Board of Trustees of ...

1. A method of determining in an individual when a complex cell population contains a clonal expansion of a subset of cells
that share a genetic sequence at a locus of interest, wherein the genetic sequence at the locus of interest is distinct from
germline sequence of the individual, and wherein the cell population exhibits high sequence heterogeneity at the locus of
interest, the method comprising:
dividing said complex cell population comprising said subset of cells that share a genetic sequence at a locus of interest,
or nucleic acids derived therefrom, into at least two distinct pools;

amplifying nucleic acid sequences selected from DNA, mRNA or a mixture of DNA and mRNA obtained from said at least two distinct
pools of said complex cell population, at the locus of interest;

sequencing at least 103 reads from the amplified nucleic acid populations at the locus of interest from said at least two distinct pools;

comparing sequences of said amplified nucleic acids at the locus of interest, to detect the presence of sequences that are
coincident in said at least two distinct pools of nucleic acid;

wherein the presence of coincident sequences in said at least two distinct pools of nucleic acids at the locus of interest,
having a sequence distinct from germline, is indicative that the complex cell population comprised a clonal expansion in a
subset of cells that share a genetic sequence at a locus of interest.

US Pat. No. 9,133,130

N-TYPE DOPED ORGANIC MATERIALS AND METHODS THEREFOR

The Board of Trustees of ...

1. A device, comprising:
an organic material, including a carbon-nanotube or graphene structure;
in a portion of the organic material, an n-type dopant material including an imidazole-based material including a hydrogen-based
material bonded between nitrogen atoms; and

wherein the n-type dopant material includes an imidazole-based material having the formula:

in which A and B include at least one of sp3- and sp2-hybridized carbon atoms, R1 includes at least one of an H atom, an alkyl group, an aryl alkyl group, an sp2-hybridized carbon
atom bonded group and borane, R2 and R3 include at least one of an H atom and at least one sp3- or sp2-hybridized carbon atom
bonded group and X includes an H atom, wherein the imidazole-based material is configured with at least one ring wherefrom
each R group (R1, R2, R3) branches, with none of R1, R2, and R3 being chemically bonded with another of R1, R2, and R3.

US Pat. No. 9,087,995

FULLERENE-DOPED NANOSTRUCTURES AND METHODS THEREFOR

The Board of Trustees of ...

1. An apparatus comprising:
a semiconducting carbon nanotube-based nanomaterial coupled between circuit nodes; and
a conductive hybrid material including a halogenated fullerene dopant and the carbon nanotube-based nanomaterial, the dopant
configured to effect a charge transfer to the carbon nanotube-based nanomaterial, and configured to electrically couple the
circuit nodes, the hybrid material exhibiting a conductivity that is higher than a conductivity of the carbon nanotube-based
nanomaterial and transparency over 90%.

US Pat. No. 9,416,155

DIRECT SENSING OF MOLECULAR SPECIES BY POLYFLUORS ON A DNA BACKBONE

The Board of Trustees of ...

1. A sensor for a target analyte having the structure:

wherein A and B are each independently a backbone group, linker, or a substrate, and may be absent or present;
each X is a backbone group independently selected from a sugar-phosphate, a phosphodiester, a phosphorothioate, a phosphotriester,
a locked nucleic acid (LNA) backbone group, a morpholino, a 2?-O-methyl RNA or a peptide nucleic acid backbone group;

n is 2 to 20; and
each R is independently a spacer, or one of the following structures:

wherein at least one R is a ligand for a metal ion, a quencher or a spacer, wherein the sensor lacks a natural DNA or RNA
base; and

wherein the sensor binds a target analyte that is selected from a metal ion and a neutral organic molecule.

US Pat. No. 9,330,907

MATERIAL QUALITY, SUSPENDED MATERIAL STRUCTURES ON LATTICE-MISMATCHED SUBSTRATES

The Board of Trustees of ...

1. A method for selectively etching a semiconductor structure, the method comprising:
providing a first region having a GeSn composition;
providing a second region having a Ge composition; and
selectively etching the second region while not etching the first region by exposing both regions to a fluorine-based isotropic
dry etch;

wherein the fluorine-based isotropic dry etch uses CF4 as an etchant.

US Pat. No. 9,320,478

DUAL-ISOTOPE POSITION EMITTING TOMOGRAPHY FOR DISEASE EVALUATION

The Board of Trustees of ...

1. A method of positron emission tomography (PET) comprising:
labeling a first probe with a first positron emitting radionuclide to provide a first labeled probe, wherein the first probe
is a selective probe that includes an antibody or ligand that is biologically responsive to receptor or antigen status;

labeling a second probe with a second positron emitting radionuclide to provide a second labeled probe, wherein the second
probe is a metabolic probe;

wherein one of the first and second radionuclides provides double coincidence events in PET by emission of a positron, and
the other of the first and second radionuclides provides triple coincidence events in PET by emission of a positron and a
gamma ray photon;

introducing the first and second labeled probes into an imaging subject simultaneously;
performing PET on the imaging subject with a PET system capable of simultaneously providing double coincidence and triple
coincidence PET images;

wherein the PET system includes a detector that is responsive to the gamma ray photon, and is not responsive to photons generated
by positron annihilation.

US Pat. No. 9,314,154

SYSTEM AND METHOD FOR PROVIDING ANALYSIS OF VISUAL FUNCTION USING A MOBILE DEVICE WITH DISPLAY

The Board of Trustees of ...

1. A method for performing a visual function evaluation of a patient with a retinal disease who is under recurrent treatment,
the method comprising:
executing a patient administered visual function evaluation on a mobile device, wherein the evaluation includes one or more
visual function tests pre-selected by a healthcare provider, wherein each test is comprised of a number of steps and the difficulty
of a subsequent step is based on a patient's response to a previous step within the test;

indicating at least one response to a pre-selected visual function test using a touch screen on the mobile device;
transmitting the visual function evaluation results from the mobile device to a remote server;
analyzing the results of the visual function evaluation using the remote server to determine trends in the patient's visual
function based on the most recent results and previous data;

analyzing the trends to determine if a next treatment is to be scheduled; and
predicting a time for the next treatment for the patient based on the trends in the patient's visual function.

US Pat. No. 9,237,658

STRONGLY COUPLED INORGANIC-GRAPHENE HYBRID MATERIALS, APPARATUSES, SYSTEMS AND METHODS

The Board of Trustees of ...

4. An apparatus comprising:
a first electrode including a nanocarbon structure and inorganic particles covalently bonded to the nanocarbon structure and
configured and arranged to facilitate transfer of charge carriers with the nanocarbon structure via the covalent bonds between
the nanocarbon structure and the inorganic particles;

a second electrode; and
a charge-passing material between the first and second electrode and configured and arranged to pass charge between the electrodes.

US Pat. No. 9,155,913

ROBOTIC LINAC ADAPTATION (RLA) FOR THE IN-LINE MRI-LINAC CONFIGURATION

The Board of Trustees of ...

1. An MRI-linac apparatus, comprising:
a. an MRI scanner, wherein the MRI scanner comprises an open bore MRI magnet that is capable of generating a magnetic field
having a fringe field, wherein said open bore MRI magnet comprises a doughnut-shape magnet, wherein said doughnut-shape comprises
a center open bore that is symmetric to said doughnut-shape, wherein said center open bore comprises a cylindrical shape having
a center axis, wherein said center axis of said center open bore is an axis of symmetry for said open bore MRI magnet; and

b. a magnetically unshielded linac comprising an electron gun, wherein the electron gun is disposed to generate an electron
beam in the presence of the fringe field, wherein the magnetically unshielded linac is displaced away from said axis of symmetry
of said open bore MRI magnet, wherein the displaced magnetically unshielded linac is disposed to output a treatment beam that
is displaced from an isocenter of said MRI-linac apparatus.

US Pat. No. 9,097,703

LIGHT CONTROLLED PROTEIN DIMERIZATION IN CELLS

THE BOARD OF TRUSTEES OF ...

1. A genetic construct comprising an expression vector encoding an L polypeptide having an interacting domain that specifically
interacts with an I polypeptide upon light activation wherein said L-polypeptide consists of the amino acid sequence of SEQ
ID NO:3 with one amino acid modification selected from the group consisting of G128D and G128E which reduces basal levels
of interaction with the I polypeptide without substantially reducing light induced interaction with the I polypeptide.

US Pat. No. 9,402,672

JOINT DISTRACTION DEVICE FOR ARTHROSCOPIC SURGERY

THE BOARD OF TRUSTEES OF ...

1. A joint distraction device for use in an arthroscopic surgery, comprising:
(a) a proximal fixation surface;
(b) a distal fixation surface; and
(c) a joint distraction mechanism, situated in between the proximal and distal surfaces, having a proximal end affixed to
the proximal fixation surface and having a distal end affixed to the distal fixation surface,

wherein the proximal fixation surface has an outer facing surface facing away from the joint distraction device, and wherein
the outer facing surface of the proximal fixation surface has two or more bone spikes for engagement with a proximal bone
segment proximally located to a joint,

wherein the distal fixation surface has an outer facing surface facing away from the joint distraction device, wherein the
outer facing surface of the distal fixation surface has one or more bone spikes for engagement with a distal bone segment
distally located from the joint,

wherein the joint distraction mechanism comprises a force driving mechanism for changing the relative distance between the
proximal fixation surface and the distal fixation surface, and wherein the force generated by the force driving mechanism
should be sufficient to insert the bone spikes into the respective bone segments, as well as distract the joint to create
a sufficient enough joint space to allow an intended procedure, and

wherein the distraction device has a size between the proximal and distal fixation surfaces that is adjustable between a shortened
position for introduction before distracting the joint that is between about 56-84 mm, and an extended position for distracting
the joint that is between about 81.6-122.4 mm,

wherein the distal distraction surface has only one bone spike.

US Pat. No. 9,308,209

IDENTIFICATION OF STABILIZERS OF MULTIMERIC PROTEINS

The Board of Trustees of ...

1. A method of decreasing TTR amyloid fibril formation, the method comprising contacting TTR with a pharmaceutical composition
comprising a compound of formula (XVII):

wherein L is a linker of about 1 to 8 atoms in length;
R51 and R52 are selected from an alkyl, an aryl, an alkoxy, an aryloxy, a hydroxyl, a heterocyclic group, a halo, a nitro and a cyano;

R53 is selected from hydrogen, an alkyl, an aryl and a heterocyclic group; and

R54 is an aryl group,

wherein the contacting decreases TTR amyloid fibril formation.

US Pat. No. 9,296,792

ORDERED FLAGELLIN ARRAY AS AN IMMUNOSTIMULANT

The Board of Trustees of ...

1. An adjuvant formulation comprising: an ordered array comprising: flagellin protein covalently linked through an unnatural
amino acid to a virus-like particle (VLP) wherein the flagellin protein is modified to: (a) comprise the unnatural amino acid
at a site corresponding to M1 of SEQ ID NO:1, wherein the unnatural amino acid is selected from homopropargylglycine (HPG),
p-acetyl-L-phenylalanine, p-propargyloxyphenylalanine, and p-azido-L-phenylalanine; and (b) methionine residues corresponding
to M310 and M466 of SEQ ID NO:1 are substituted with a non-polar amino acid other than methionine; and a pharmaceutically
acceptable excipient.

US Pat. No. 9,248,120

REVERSING INTESTINAL INFLAMMATION BY INHIBITING RETINOIC ACID METABOLISM

THE BOARD OF TRUSTEES OF ...

1. A method of reducing chronic intestinal inflammation in an individual with familial adenomatous polyposis (FAP), the method
comprising:
administering to the individual an effective dose of an agent that increases local concentration of retinoic acid (RA) through
modifying enzymatic pathways involved in RA metabolism, wherein the agent is not retinoic acid, and wherein inflammation is
reduced.

US Pat. No. 9,234,229

HIGH THROUGHPUT SYSTEM FOR ISOLATION, GROWTH, AND DETECTION OF LIPID INCLUSIONS IN BACTERIA

The Board of Trustees of ...

1. A method of providing a high throughput growth and quantitative analysis of microorganisms, comprising:
a. screening a throughput of cultures for bioplastic enrichment from an array of lipid producing bacteria using a microtiter
plate growth and gas delivery system, wherein said microtiter plate growth and gas delivery system comprises well plates disposed
for growth of microorganisms and a spectroscopic screening system disposed for analyzing said bioplastic and a gas delivery
system comprising controlled gas flow of methane, nitrogen, oxygen, carbon dioxide, carbon monoxide, hydrogen, ethane, propane,
or other gaseous hydrocarbons as a continuous gradient along the microtiter plate;

b. isolating lipid producing bacteria of said bioplastic;
c. inducing production of bioplastic;
d. determining a growth condition for enriching bioplastic production using said spectroscopic screening of said microtiter
plate growth and gas delivery system.

US Pat. No. 9,197,805

DIGITAL MULTIPLEXING READOUT FOR SPARSE SIGNALS ON IMAGING ARRAYS

The Board of Trustees of ...

1. A method for providing an image from a device with a plurality of sensors and a plurality of time to digital converters
(TDC) comprising:
generating data signals from some of the plurality of sensors, wherein each sensor of the plurality of sensors provides output
in parallel to more than one TDC of the plurality of TDCs and wherein each TDC of the plurality of TDCs receives in parallel
input from more than one sensor of the plurality of sensors, wherein a binary matrix indicates which sensors are connected
to which TDC;

transmitting the data signals from the sensors to the TDCs;
generating TDC signals from the data signals; and
using group testing to decode the TDC signals based on the binary matrix.

US Pat. No. 9,151,732

ENHANCED ISOTACHOPHORESIS ASSAYS USING ADDITIVES WITH SPATIAL GRADIENTS

THE BOARD OF TRUSTEES OF ...

1. an isotachophoresis method comprising:
forming a concentration gradient of each of one or more additives along a channel from an input port configured to receive
a sample to an output port, wherein:

the channel further comprises ions of a leading electrolyte having a first effective mobility magnitude greater than an effective
mobility magnitude of an analyte, and ions of a trailing electrolyte having a second effective mobility magnitude less than
the effective mobility magnitude of the analyte;

each additive is different from both the leading electrolyte and the trailing electrolyte;
each additive has a third mobility that assures the analyte will encounter the additive; and
each additive operates on a component of the sample only in a portion of the channel;
contacting the sample including the analyte to the leading electrolyte;
contacting the trailing electrolyte to the sample;
applying an electric field to the channel; and
measuring the analyte.

US Pat. No. 9,140,701

FIBRINOGEN IMMUNE COMPLEXES TO DIAGNOSE AND GUIDE THERAPY IN RHEUMATOID ARTHRITIS

THE BOARD OF TRUSTEES OF ...

1. A method for the prognosis of the severity of rheumatoid arthritis in a human individual, the method comprising:
detecting circulating immune complexes containing citrullinated fibrinogen and immunoglobulin in a sample of blood or derivative
therefrom obtained from the individual;

analyzing the fibrinogen immune complex content in said sample relative to a normal control by contacting the blood sample
with C1q protein;

contacting immune complexes bound to the C1q protein with an agent that selectively binds to fibrinogen;
detecting the presence of a fibrinogen containing immune complexes;
wherein the presence of said fibrinogen containing immune complexes, compared to a control sample, is indicative of positive
binding; and

providing an assessment of prognosis for said individual, where the presence of the immune complexes containing fibrinogen
is indicative of a more severe disease prognosis.

US Pat. No. 9,115,384

METHODS AND COMPOSITIONS FOR DETECTING RECEPTOR-LIGAND INTERACTIONS IN SINGLE CELLS

The Board of Trustees of ...

1. A composition for determining the activation profile of one or more cells, the composition comprising:
a sample comprising one or more cells;
a first activation state specific binding member specific for an isoform corresponding to an activation state of a first activatable
element, wherein the first activatable element comprises a first activation state and a second activation state; and

a second activation state specific binding member specific for an isoform corresponding to an activation state of a second
activatable element, wherein the second activatable element comprises a first activation state and a second activation state,
and wherein the first and the second activatable elements are different and are distinguishably detectable from one another;

wherein the first and second activation state specific binding members detect binding to their corresponding activatable elements
simultaneously or sequentially in single cells bound to their corresponding activatable element inside the one or more cells
and said binding indicates the activation profile of each of the one or more cells in the sample.

US Pat. No. 9,101,759

MATERIALS AND APPROACHES FOR OPTICAL STIMULATION OF THE PERIPHERAL NERVOUS SYSTEM

THE BOARD OF TRUSTEES OF ...

1. A method of modulating the activity of motor units in size order, the method comprising:
a) genetically modifying motor neurons, in a set of motor units that includes motor units having motor neurons of different
physical sizes, to express a light-responsive ion channel or a light-responsive ion pump; and

b) activating or inhibiting the light-responsive ion channel or light-responsive ion pump by providing an optical stimulus
to the light-responsive ion channel or light-responsive ion pump, thereby recruiting the motor units according to the physical
size of motor neurons within the motor units, such that activity of the motor units is modulated in order from small to large.

US Pat. No. 9,075,010

ENHANCEMENT OF MOLECULAR EMISSION USING OPTICAL-ANTENNA STRUCTURES

The Board of Trustees of ...

1. An apparatus comprising:
a nano-antenna of at least two metallic end portions on a support structure;
the nano-antenna configured and arranged
with fluorescence-enhancing molecules fixed to a surface of the metallic end portions in a gap between the at least two metallic
end portions whereat a fluid solution of fluorescent molecules can reside,

to receive and respond to optical energy by generating an electric field due to opposing charges via the at least two metallic
end portions, each of the end portions being configured and arranged with a width that increases with distance away from the
gap and therein concentrates the electric field within the gap, and

to use the opposing charges and the fluorescence-enhancing molecules to concentrate and enhance the electric field and fluorescence
emission of the fluorescent molecules in the fluid solution when the fluid solution resides between the at least two metallic
end portions; and

a photon-counting circuit configured and arranged to sense, due to the fluorescence of the fluorescent molecules, life-time
or broadly peaking characteristics of spectral waveforms.

US Pat. No. 9,057,673

METHOD OF PREPARING RNA FROM RIBONUCLEASE-RICH SOURCES

The Board of Trustees of ...

1. A method of preparing RNA from a biological sample, the method comprising performing the following steps:
a) adding a reducing agent to the biological sample;
b) adding a lysis solution to the biological sample to produce a mixture, wherein the lysis solution comprises a first reagent
that causes the mixture to have a pH equal to or greater than 10;

c) incubating the biological sample with the lysis solution for up to 5 minutes to produce a lysate; and
d) adding a second reagent to the lysate to lower the pH of the lysate to a level at which the RNA is stable;wherein steps (a)-(d) are performed without heating the biological sample and in the absence of other additional agents that
inhibit polymerases or reverse transcriptases.
US Pat. No. 9,274,099

SCREENING TEST DRUGS TO IDENTIFY THEIR EFFECTS ON CELL MEMBRANE VOLTAGE-GATED ION CHANNEL

The Board of Trustees of ...

1. A method for screening test drugs to identify their effects on cell membrane voltage-gated ion channel, the method comprising:
a) contacting a mammalian cell with a test drug, wherein the cell: is genetically modified to express a heterologous, microbial
light-responsive ChR2 ion channel comprising an amino acid sequence having at least 75% amino acid sequence identity to SEQ
ID NO: 1, wherein the heterologous ChR2 ion channel, when activated by light, results in a change in the voltage in the cell
membrane; wherein the cell comprises: i) a voltage-gated ion channel that causes a change in the intracellular concentration
of an ion in response to the light-induced change in voltage; and ii) an indicator that produces a fluorescent signal in response
to a change in the intracellular concentration of the ion; b) activating the heterologous, microbial light responsive ChR2
ion channel with light; c) detecting a fluorescent signal produced by the indicator; processing data received from the indicator;
and storing the processed data received from the indicator, wherein a change in the signal produced by the indicator in the
presence of the test drug, compared to the signal produced in the absence of the test drug, indicates that the test drug is
a candidate drug that affects the voltage-gated ion channel.

US Pat. No. 9,246,078

PIEZOELECTRIC APPARATUSES, SYSTEMS AND METHODS THEREFOR

The Board of Trustees of ...

1. An apparatus comprising:
a nanomaterial; and
structures coupled to the nanomaterial and configured and arranged with the nanomaterial to manifest piezoelectric characteristics
via interaction between the structures and nanomaterial, wherein the structures are configured and arranged with the nanomaterial
to manifest the piezoelectric characteristics in regions of the nanomaterial, via interaction between the structures and nanomaterial
that alters an inversion symmetry characteristic of the nanomaterial.

US Pat. No. 9,061,010

METHODS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION AND COMPOSITIONS FOR TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION

The Board of Trustees of ...

1. A method of treating a host infected with Hepatitis C virus, the method comprising administering to the host a therapeutically
effective amount of an inhibiting agent, or a pharmaceutical salt thereof, to reduce the viral load in the host, wherein the
inhibiting agent is a compound having the formula:

wherein R1 is selected from the group consisting of


R2 is selected from the group consisting of: —H, —CH3, —CF3, —CH2CH3, CH2OH,

and
R4 to R7 are each independently selected from the group consisting of: —H, —CH3, and a halogen.

US Pat. No. 9,601,452

HIGH-CONDUCTIVITY BONDING OF METAL NANOWIRE ARRAYS

Northrup Grumman Systems ...

1. A thermally-conductive and mechanically-robust bonding method for attaching a metal nanowire (MNW) array to an adjacent
surface, comprising the steps of:
choosing a bonding material based on a desired bonding process; and
without removing the MNW from a template membrane that fills an interstitial volume of the MNW array, depositing the bonding
material onto a tip of the MNW, wherein the MNW array is substantially filled to the thickness of the template membrane,

wherein the step of depositing comprises depositing caps of bonding material onto tips of the MNWs.

US Pat. No. 9,468,989

HIGH-CONDUCTIVITY BONDING OF METAL NANOWIRE ARRAYS

Northrop Grumman Systems ...

1. A thermally-conductive and mechanically-robust bonding method for attaching a metal nanowire (MNW) array to an adjacent
surface, comprising the steps of:
removing a template membrane from the MNW array;
infiltrating the MNW array with a bonding material;
placing the bonding material on the adjacent surface;
bringing an adjacent surface into contact with a top surface of the MNW array while the bonding material is bondable; and
allowing the bonding material to form a solid bond between the MNW array and the adjacent surface.

US Pat. No. 9,470,651

ELECTRO-DIFFUSION ENHANCED BIO-MOLECULE CHARGE DETECTION USING ELECTROSTATIC INTERACTION

The Board of Trustees of ...

1. An apparatus comprising:
a substrate securing a channel located along a surface of the substrate, the channel having an effective width that is not
limited by the Debye screening length;

at least one reservoir configured for containing and presenting a sample having bio-molecules for delivery in the channel;
a first electrode and a second electrode, each of the electrodes configured for electrically coupling a charge in the sample
to enhance ionic current flow therein;

at least one sense electrode structure including one buried electrode to detect charges of the bio-molecules that are electrically
driven along surfaces of the channel and located along the channel, and configured for sensing a characteristic of the sample
at least partly based on electrostatic interaction between the enhanced ionic current flow of the sample and the at least
one sense electrode structure; and

a charge-signal circuit coupled to the at least one sense electrode structure, and configured for processing a signal carried
therefrom and providing an output useful for identifying a type of the bio-molecules delivered in the channel.

US Pat. No. 9,403,895

PRODUCTION AND DELIVERY OF A STABLE COLLAGEN

The Board of Trustees of ...

1. A method of delivering collagen VII to the dermal layer of skin, the method comprising:
fabricating an array of biodegradable microneedles comprising collagen VII incorporated into the microneedles; and
contacting the skin of an individual with said array with a pressure sufficient to penetrate the skin to the depth of anchoring
fibrils.

US Pat. No. 9,161,968

METHODS OF NEUROPROTECTION INVOLVING MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR AGONISTS

The Board of Trustees of ...

1. A method of attenuating neuronal damage in a human subject suffering from traumatic brain injury, the method comprising:
administering a therapeutically effective amount of a pharmaceutical composition comprising at least one of CSF-1 and Interleukin-34
to said human subject within six hours following said traumatic brain injury to attenuate neuronal damage in said human subject.

US Pat. No. 9,150,559

ANTI-PROLIFERATIVE COMPOUNDS AND METHODS FOR USING THE SAME

The Board of Trustees of ...

1. A method of inhibiting the growth of leukemia cells, wherein the leukemia cells comprise a genetic abnormality in the MLL
gene, the method comprising contacting the leukemia cells with an effective dose of a compound of the structure:

US Pat. No. 9,087,241

INTELLIGENT PART IDENTIFICATION FOR USE WITH SCENE CHARACTERIZATION OR MOTION CAPTURE

The Board of Trustees of ...

1. A method comprising:
generating a three-dimensional surface mesh from three-dimensional (3D) image data corresponding to a physical structure;
categorizing lengths of paths on the three-dimensional surface mesh according to geodesic distances between a plurality of
points on the three-dimensional surface mesh and a common reference point, the paths connected to one or more points of the
plurality of points on the three-dimensional surface mesh;

identifying a subset of the plurality of points as salient points based upon the categorized lengths of paths and therefrom
characterizing the physical structure including body part types; and

using descriptor patches for each of different body part types, wherein the descriptor patches correspond to subsets of the
mesh and approximate a uniform distribution over the mesh surface.

US Pat. No. 9,080,176

MULTIMODALITY IMAGING OF REPORTER GENE EXPRESSION USING A NOVEL FUSION VECTOR IN LIVING CELLS AND ANIMALS

The Board of Trustees of ...

1. A double fusion nucleic acid expression vector, comprising:
a first reporter nucleic acid sequence, a second reporter nucleic acid sequence, and a linker sequence, wherein:
(i) the first reporter nucleic acid sequence, the second reporter nucleic acid sequence, and the nucleic acid linker sequence,
are operably linked to an expression control system and co-expressible as a single fusion polypeptide therefrom;

(ii) the first reporter nucleic acid sequence and the second reporter nucleic acid sequence are separated from each other
by the nucleic acid linker sequence;

(iii) each of the first and second reporter nucleic acid sequences encodes an individual imageable reporter region of the
expressed fusion polypeptide;

(iv) each of the individual imageable reporter regions of the fusion polypeptide is imageable by a method selected from the
group consisting of: detecting bioluminescence, detecting fluorescence, and positron emission topography, wherein no two reporter
regions are imageable by the same method; and

(v) the nucleic acid linker sequence encodes a polypeptide linker having an amino acid sequence selected from the group consisting
of: SEQ ID NOs: 9 and 10.

US Pat. No. 9,737,875

AFFINITY REAGENTS FOR PROTEIN PURIFICATION

Impossible Foods Inc., R...

1. A compound comprising the structure

wherein the wavy line indicates the point of attachment to a substrate, optionally through a linker;
wherein R1 is selected from the group consisting of 2-phenylpropylamine, 4-methylbenzylamine, 2-phenylethanamine, benzylamine, 3-phenylpropylamine,
4-(2-aminomethyl)benzenesulfonamide, 2-methylbutylamine, isoamylamine, isobutylamine, butylamine, propargylamine, piperazine,
ethylamine, 1-amino-3,3-diethoxypropane, 4-amino-2-methyl-1-butanol, 5-amino-1-pentanol, acetamide, 2-amino-N-cyclopropyl-1-amino-2-butanol,
N,N-bis(2-aminoethyl)ethane-1,2-diamine, N,N,2,2-tetramethyl-1,3-propanediamine, N,N-diethyl-1,3-propanediamine, N1-(2-aminoethyl)-N1-methylethane-1,2-diamine,
N,N-dimethyl-1,3-propanediamine, 4-(difluoromethoxy)benzylamine, 2-N-propoxyethylamine, 2-methoxyethylamine, N-tert-butoxycarbonyl-3-aminopropanamine,
3-isopropoxypropylamine, 3-(methylthio)propylamine, 2-aminoethyl isopropyl ether, 4-bromo-2-fluorobenzylamine, 4-iodobenzylamine,
4-bromobenzylamine, 2-(4-nitro-phenyl)-ethylamine, 3-fluoro-5-(trifluoromethyl)benzylamine, 4-nitro-benzylamine, 3-bromobenzylamine,
3-chloro-2,6-difluorobenzylamine, 3,4-dichlorobenzylamine, 4-(trifluoromethyl)benzylamine, 2-(3-chlorophenyl)ethylamine, 2-(4-chlorophenyl)ethylamine,
3-chlorobenzylamine, 2-chlorobenzylamine, 3-fluorophenethylamine, 4-fluorophenethylamine, 3-fluorobenzylamine, tetrahydrofurfurylamine,
4-(2-aminoethyl)-1-benzylpiperidine, (2,2-dimethyl-[1,3]-dioxolan-4-yl)-methylamine, N-(3-aminopropyl)morpholine, 4-(2-aminoethyl)morpholine,
2-(2-aminoethyl)-1-methylpyrrolidine, 4-(aminomethyl)piperidine, 2-(aminomethyl)-1-ethylpyrrolidine, 4-pyrrolidinobutylamine,
1-(3-aminopropyl)pyrrolidine, 1-(3-aminopropyl)-4-methylpiperazine, N-(3?-aminopropyl)-2-pyrrolidinone, ethyl 4-amino-1-piperidinecarboxylate,
ethanone, 2-amino-1-(4-morpholinyl)-3-aminopropane-1,2-diol, 3-aminopropionitrile, 3-amino-1-propanol, 2-(2-aminoethoxy)ethanol,
2-(1h-indol-3-yl)ethanamine (tryptamine), 3-(2-aminoethyl)pyridine, 1h-indole-2-methanamine, acetamide, 2-amino-N-(1-methylethyl)-,
2-(2-methoxyphenyl)ethylamine, 2-(aminomethyl)pyridine, 4-(2-aminoethyl)pyridine, 2-thiophenemethylamine, 4-(aminomethyl)pyridine,
3-(aminomethyl)pyridine, 3-bromo-4-methoxyphenethylamine, 3-furanmethanamine, 2-quinolinemethanamine, homopiperazine, propanamide,
3-amino-N-methyl-, 2-(2-furylmethylthio)ethanamine, 4-(2-aminoethyl)benzenesulfonamide, 5-aminomethyl-2-chloropyridine, 5-methoxytryptamine,
N-acetylethylenediamine, s-(2-aminoethyl)isothiouronium bromide, homotaurine, (r)-1-(3-methoxyphenyl)ethylamine, 2-(3,4-dimethoxyphenyl)ethylamine,
3-methoxyphenethylamine, 2-(4-methoxyphenyl)ethylamine, 4-methoxybenzylamine, 2-phenoxyethylamine, 2-methoxybenzylamine, and
3-methoxybenzylamine;

R2 is selected from the group consisting of 2-phenylpropylamine, 4-methylbenzylamine, 2-phenylethanamine, benzylamine, 3-phenylpropylamine,
4-(2-aminomethyl)benzenesulfonamide, 2-methylbutylamine, isoamylamine, isobutylamine, butylamine, propargylamine, piperazine,
ethylamine, 1-amino-3,3-diethoxypropane, 4-amino-2-methyl-1-butanol, 5-amino-1-pentanol, acetamide, 2-amino-N-cyclopropyl-,
1-amino-2-butanol, N,N-bis(2-aminoethyl)ethane-1,2-diamine, n,n,2,2-tetramethyl-1,3-propanediamine, N,N-diethyl-1,3-propanediamine,
n1-(2-aminoethyl)-n1-methylethane-1,2-diamine, N,N-dimethyl-1,3-propanediamine, 4-(difluoromethoxy)benzylamine, 2-N-propoxyethylamine,
2-methoxyethylamine, N-tert-butoxycarbonyl-3-aminopropanamine, 3-isopropoxypropylamine, 3-(methylthio)propylamine, 2-aminoethyl
isopropyl ether, 4-bromo-2-fluorobenzylamine, 4-iodobenzylamine, 4-bromobenzylamine, 2-(4-nitro-phenyl)-ethylamine, 3-fluoro-5-(trifluoromethyl)benzylamine,
4-nitro-benzylamine, 3-bromobenzylamine, 3-chloro-2,6-difluorobenzylamine, 3,4-dichlorobenzylamine, 4-(trifluoromethyl)benzylamine,
2-(3-chlorophenyl)ethylamine, 2-(4-chlorophenyl)ethylamine, 3-chlorobenzylamine, 2-chlorobenzylamine, 3-fluorophenethylamine,
4-fluorophenethylamine, 3-fluorobenzylamine, tetrahydrofurfurylamine, 4-(2-aminoethyl)-1-benzylpiperidine, (2,2-dimethyl-[1,3]-dioxolan-4-yl)-methylamine,
N-(3-aminopropyl)morpholine, 4-(2-aminoethyl)morpholine, 2-(2-aminoethyl)-1-methylpyrrolidine, 4-(aminomethyl)piperidine,
2-(aminomethyl)-1-ethylpyrrolidine, 4-pyrrolidinobutylamine, 1-(3-aminopropyl)pyrrolidine, 1-(3-aminopropyl)-4-methylpiperazine,
N-(3?-aminopropyl)-2-pyrrolidinone, ethyl 4-amino-1-piperidinecarboxylate, ethanone, 2-amino-1-(4-morpholinyl)-, 3-aminopropane-1,2-diol,
3-aminopropionitrile, 3-amino-1-propanol, 2-(2-aminoethoxy)ethanol, 2-(1H-indol-3-yl)ethanamine (tryptamine), 3-(2-aminoethyl)pyridine,
1H-indole-2-methanamine, acetamide, 2-amino-N-(1-methylethyl)-, 2-(2-methoxyphenyl)ethylamine, 2-(aminomethyl)pyridine, 4-(2-aminoethyl)pyridine,
2-thiophenemethylamine, 4-(aminomethyl)pyridine, 3-(aminomethyl)pyridine, 3-bromo-4-methoxyphenethylamine, 3-furanmethanamine,
2-quinolinemethanamine, homopiperazine, propanamide, 3-amino-N-methyl-, 2-(2-furylmethylthio)ethanamine, 4-(2-aminoethyl)benzenesulfonamide,
5-aminomethyl-2-chloropyridine, 5-methoxytryptamine, N-acetylethylenediamine, s-(2-aminoethyl)isothiouronium bromide, homotaurine,
(r)-1-(3-methoxyphenyl)ethylamine, 2-(3,4-dimethoxyphenyl)ethylamine, 3-methoxyphenethylamine, 2-(4-methoxyphenyl)ethylamine,
4-methoxybenzylamine, 2-phenoxyethylamine, 2-methoxybenzylamine, 3-methoxybenzylamine, (z)-4-chloro-2-buten-1-amine, 2-(1-cyclohexenyl)ethylamine,
3-methoxypropylamine, 3-ethoxypropylamine, 3-N-propoxypropylamine, 2-ethoxyethylamine, 3-iodobenzylamine, 3-(trifluoromethyl)benzylamine,
4-(4-fluorophenoxy)benzylamine, 3,4-methylenedioxybenzylamine, 8-quinolinemethanamine, 4-pyridinemethanamine, 2-(dimethylamino)-,
2-aminoethyl hydrogen sulfate, aminomethanesulfonic acid, 3,4,5-trimethoxybenzylamine, dl-1-(1-naphthyl)ethylamine, (s)-(?)-1-(4-methylphenyl)ethylamine,
(s)-(?)-beta-methylphenethylamine, (r)-(?)-1-aminoindan, (s)-(?)-1-phenylethylamine, (r)-(+)-1-phenylethylamine, 1-phenylbutan-3-amine,
d-phenylalaninol, (1r,2s)-1-amino-2-indanol, 2-amino-3,3-dimethylbutane, 1,3-dimethylbutylamine, sec-butylamine, isopropylamine,
2-amino-1-methoxybutane, (s)-2-amino-1-phenylethanol, (s)-(+)-2-amino-1-pentanol, (r)-(?)-2-amino-1-butanol, 1-leucinamide,
cyclopentylamine, cyclopropylamine, trans-4-aminocyclohexanol, (1s,2s)-(+)-2-benzyloxycyclohexylamine, (1r,2r)-(?)-2-benzyloxycyclopentylamine,
2-(2-chlorophenyl)ethylamine, 2-fluorophenethylamine, (1r,2r)-(?)-2-amino-1-(4-nitrophenyl)-1,3-propanediol, 4-aminotetrahydropyran,
dl-homocysteine thiolactone, dl-?-amino-?-caprolactam, indan-5-ylamine, 4-aminopyridine, N-(3-aminopropyl)-N-methylaniline,
2-fluoroethanamine, alpha-phenylglycinonitrile, (1r,2r)-(?)-2-amino-1-phenyl-1,3-propanediol, beta alanine napthylamide, 1-leucine-4-nitroanilide,
2-amino-3-methyl-3-sulfanylbutanoic acid, (s)-(?)-1-(3-methoxyphenyl)ethylamine, (s)-(?)-1-(4-methoxyphenyl)ethylamine, trans-2,5-dimethylpiperazine,
9-aminofluorene, 2,4,6-trimethylaniline, 2,4-dimethylaniline, 3,5-dimethyl aniline, 2,5-dimethylaniline, 2-methylaniline,
2,6-diethylaniline, 3-isopropylaniline, 4-isopropylaniline, m-aminobenzoylamine, 4-aminobenzamide, 3-nitroaniline, 2,6-difluoroaniline,
3?,4?-difluoroaniline, 3-chloroaniline, 2-chloroaniline, 2-fluoro-aniline, 4-fluoroaniline, 3,4-methylenedioxy-1-aminobenzene,
2-aminopyrazine, 3-aminopyridine, 2-aminopyridine, 4-methyl-1,3-thiazol-2-amine, 2-aminopyrimidine, 5-amino-1h-tetrazole,
4-ethoxyaniline, 2-(methylmercapto)aniline, 2-ethoxyaniline, o-anisidine, and 4-amino-1-butanol;

R3 is selected from the group consisting of 2-phenylpropylamine, 4-methylbenzylamine, 2-phenylethanamine, benzylamine, 3-phenylpropylamine,
4-(2-aminomethyl)benzenesulfonamide, 2-methylbutylamine, isoamylamine, isobutylamine, butylamine, propargylamine, piperazine,
ethylamine, 4-amino-2-methyl-1-butanol, 5-amino-1-pentanol, acetamide, 2-amino-N-cyclopropyl-, 1-amino-2-butanol, N,N-bis(2-aminoethyl)ethane-1,2-diamine,
n,n,2,2-tetramethyl-1,3-propanediamine, N,N-diethyl-1,3-propanediamine, n1-(2-aminoethyl)-n1-methylethane-1,2-diamine, N,N-dimethyl-1,3-propanediamine,
4-(difluoromethoxy)benzylamine, 3-(methylthio)propylamine, 4-bromo-2-fluorobenzylamine, 4-bromobenzylamine, 2-(4-nitro-phenyl)-ethylamine,
3-fluoro-5-(trifluoromethyl)benzylamine, 4-nitro-benzylamine, 3-bromobenzylamine, 3-chloro-2,6-difluorobenzylamine, 3,4-dichlorobenzylamine,
4-(trifluoromethyl)benzylamine, 2-(3-chlorophenyl)ethylamine, 3-chlorobenzylamine, 2-chlorobenzylamine, 3-fluorophenethylamine,
4-fluorophenethylamine, tetrahydrofurfurylamine, 4-(2-aminoethyl)-1-benzylpiperidine, (2,2-dimethyl-[1,3]-dioxolan-4-yl)-methylamine,
N-(3-aminopropyl)morpholine, 4-(2-aminoethyl)morpholine, 2-(2-aminoethyl)-1-methylpyrrolidine, 4-(aminomethyl)piperidine,
2-(aminomethyl)-1-ethylpyrrolidine, 4-pyrrolidinobutylamine, 1-(3-aminopropyl)-4-methylpiperazine, N-(3?-aminopropyl)-2-pyrrolidinone,
ethyl 4-amino-1-piperidinecarboxylate, ethanone, 2-amino-1-(4-morpholinyl)-, 3-aminopropane-1,2-diol, 3-aminopropionitrile,
3-amino-1-propanol, 2-(2-aminoethoxy)ethanol, 2-(1h-indol-3-yl)ethanamine (tryptamine), 3-(2-aminoethyl)pyridine, 1h-indole-2-methanamine,
acetamide, 2-amino-N-(1-methylethyl)-, 2-(2-methoxyphenyl)ethylamine, 2-(aminomethyl)pyridine, 4-(2-aminoethyl)pyridine, 4-(aminomethyl)pyridine,
3-(aminomethyl)pyridine, 3-bromo-4-methoxyphenethylamine, 3-furanmethanamine, 2-quinolinemethanamine, homopiperazine, propanamide,
3-amino-N-methyl-, 2-(2-furylmethylthio)ethanamine, 4-(2-aminoethyl)benzenesulfonamide, 5-methoxytryptamine, N-acetylethylenediamine,
(r)-1-(3-methoxyphenyl)ethylamine, 2-(3,4-dimethoxyphenyl)ethylamine, 2-(4-methoxyphenyl)ethylamine, 4-methoxybenzylamine,
2-phenoxyethylamine, 2-methoxybenzylamine, 3-methoxybenzylamine, (z)-4-chloro-2-buten-1-amine, 2-(1-cyclohexenyl)ethylamine,
3-methoxypropylamine, 3-ethoxypropylamine, 3-N-propoxypropylamine, 2-ethoxyethylamine, 3-iodobenzylamine, 3-(trifluoromethyl)benzylamine,
4-(4-fluorophenoxy)benzylamine, 3,4-methylenedioxybenzylamine, 8-quinolinemethanamine, 4-pyridinemethanamine, 2-(dimethylamino)-,
2-aminoethyl hydrogen sulfate, aminomethanesulfonic acid, 3,4,5-trimethoxybenzylamine, dl-1-(1-naphthyl)ethylamine, (s)-(?)-1-(4-methylphenyl)ethylamine,
1-phenylbutan-3-amine, d-phenylalaninol, (1r,2s)-1-amino-2-indanol, 2-amino-3,3-dimethylbutane, 1,3-dimethylbutylamine, 2-amino-1-methoxybutane,
(s)-2-amino-1-phenylethanol, (s)-(+)-2-amino-1-pentanol, 1-leucinamide, cyclopentylamine, cyclopropylamine, trans-4-aminocyclohexanol,
(1s,2s)-(+)-2-benzyloxycyclohexylamine, (1r,2r)-(?)-2-benzyloxycyclopentylamine, 2-(2-chlorophenyl)ethylamine, 2-fluorophenethylamine,
(1r,2r)-(?)-2-amino-1-(4-nitrophenyl)-1,3-propanediol, 4-aminotetrahydropyran, dl-homocysteine thiolactone, dl-alpha-amino-epsilon-caprolactam,
indan-5-ylamine, 4-aminopyridine, 2-(aminomethyl)piperidine, 1-(3-aminopropyl)-2-pipecoline, benzenepropanoic acid, ?-(aminomethyl)-,
benzeneacetic acid, ?-(aminomethyl)-, benzoic acid, 2-(aminomethyl)-, 6-aminocaproic acid, pentanoic acid, 5-amino-, cyclohexanecarboxylic
acid, 4-(aminomethyl)-, (2s)-4-amino-2-hydroxy-butyric acid, N-(3-aminopropyl)-N-methylaniline, tyramine, phenol, 3-(aminomethyl)-,
3-methoxytyramine, 2-fluoroethanamine, 3-aminopyrrolidine, 4-aminopiperidine, phenylalanine, 3,5-dimethyl-, glutamic acid,
d-phenylalanine, 3-fluoro-, benzeneacetic acid, ?-amino-4-fluoro-, tyrosine, 3-fluoro-, 4-pyridinepropanoic acid, ?-amino-,
(?r)-, asparagine, alpha-phenylglycinonitrile, (1r,2r)-(?)-2-amino-1-phenyl-1,3-propanediol, beta alanine napthylamide, l-leucine-4-nitroanilide,
2-amino-3-methyl-3-sulfanylbutanoic acid, 1,2,3,4-tetrahydro-1-naphthylamine, (s)-(?)-1-(3-methoxyphenyl)ethylamine, (s)-(?)-1-(4-methoxyphenyl)ethylamine,
trans-2,5-dimethylpiperazine, cis-2, 6 dimethylpiperazine, 3-pyrrolidinecarboxylic acid, 1h-imidazole, 1-(3-pyrrolidinyl)-,
pyrrolidine, 3-(methyl sulfonyl)-, 3-pyrrolidinecarboxamide, 9-aminofluorene, 2,6-diethylaniline, meta-aminobenzoylamine,
3-nitroaniline, 3,4-methylenedioxy-1-aminobenzene, 2-aminopyrazine, 4-ethoxyaniline, 1h-indol-5-ol, 3-(2-aminoethyl)-, d-phenylalanine,
glutamine, benzenepropanoic acid, ?-amino-3,4-dihydroxy-, butanoic acid, 2-amino-4,4,4-trifluoro-, butanoic acid, 2-amino-3-hydroxy-,
3-thiophenepropanoic acid, ?-amino-, 3-thiopheneacetic acid, ?-amino-, 2-morpholineacetic acid, benzoic acid, 4-amino-3-hydroxy-,
1h-pyrazole-3-carboxylic acid, 5-amino-, 4-amino-1-butanol, and 4-dimethylaminobenzylamine; and

R4 is selected from the group consisting of 2-phenylpropylamine, 4-methylbenzylamine, 2-phenylethanamine, benzylamine, 3-phenylpropylamine,
4-(2-aminomethyl)benzenesulfonamide, 2-methylbutylamine, isoamylamine, isobutylamine, butylamine, propargylamine, (z)-4-chloro-2-buten-1-amine,
2-(1-cyclohexenyl)ethylamine, 3-methoxypropylamine, 3-ethoxypropylamine, 3-N-propoxypropylamine, 2-ethoxyethylamine, 3-iodobenzylamine,
3-(trifluoromethyl)benzylamine, 4-(4-fluorophenoxy)benzylamine, 3,4-methylenedioxybenzylamine, 8-quinolinemethanamine, 4-pyridinemethanamine,
2-(dimethylamino)-, piperazine, ethylamine, 1-amino-3,3-diethoxypropane, 4-amino-2-methyl-1-butanol, 5-amino-1-pentanol, acetamide,
2-amino-N-cyclopropyl-, 1-amino-2-butanol, N,N-bis(2-aminoethyl)ethane-1,2-diamine, n,n,2,2-tetramethyl-1,3-propanediamine,
N,N-diethyl-1,3-propanediamine, n1-(2-aminoethyl)-n1-methylethane-1,2-diamine, N,N-dimethyl-1,3-propanediamine, 3,4,5-trimethoxybenzylamine,
dl-1-(1-naphthyl)ethylamine, (s)-(?)-1-(4-methylphenyl)ethylamine, (s)-(?)-beta-methylphenethylamine, (r)-(?)-1-aminoindan,
(s)-(?)-1-phenylethylamine, (r)-(+)-1-phenylethylamine, 1-phenylbutan-3-amine, d-phenylalaninol, (1r,2s)-1-amino-2-indanol,
2-amino-3,3-dimethylbutane, 1,3-dimethylbutylamine, 4-(difluoromethoxy)benzylamine, 2-N-propoxyethylamine, 2-methoxyethylamine,
N-tert-butoxycarbonyl-3-aminopropanamine, 3-isopropoxypropylamine, 3-(methylthio)propylamine, 2-aminoethyl isopropyl ether,
4-bromo-2-fluorobenzylamine, 4-iodobenzylamine, 4-bromobenzylamine, 2-(4-nitro-phenyl)-ethylamine, 3-fluoro-5-(trifluoromethyl)benzylamine,
sec-butylamine, isopropylamine, 2-amino-1-methoxybutane, (s)-2-amino-1-phenylethanol, (s)-(+)-2-amino-1-pentanol, (r)-(?)-2-amino-1-butanol,
1-leucinamide, cyclopentylamine, cyclopropylamine, trans-4-aminocyclohexanol, (1s,2s)-(+)-2-benzyloxycyclohexylamine, (1r,2r)-(?)-2-benzyloxycyclopentylamine,
4-nitro-benzylamine, 3-bromobenzylamine, 3-chloro-2,6-difluorobenzylamine, 3,4-dichlorobenzylamine, 4-(trifluoromethyl)benzylamine,
2-(3-chlorophenyl)ethylamine, 2-(4-chlorophenyl)ethylamine, 3-chlorobenzylamine, 2-chlorobenzylamine, 3-fluorophenethylamine,
4-fluorophenethylamine, 3-fluorobenzylamine, 2-(2-chlorophenyl)ethylamine, 2-fluorophenethylamine, (1r,2r)-(?)-2-amino-1-(4-nitrophenyl)-1,3-propanediol,
4-aminotetrahydropyran, dl-homocysteine thiolactone, dl-?-amino-epsilon-caprolactam, indan-5-ylamine, 4-aminopyridine, 2-(aminomethyl)piperidine,
1-(3-aminopropyl)-2-pipecoline, benzenepropanoic acid, ?-(aminomethyl)-, benzeneacetic acid, ?-(aminomethyl)-, tetrahydrofurfurylamine,
4-(2-aminoethyl)-1-benzylpiperidine, (2,2-dimethyl-[1,3]-dioxolan-4-yl)-methylamine, N-(3-aminopropyl)morpholine, 4-(2-aminoethyl)morpholine,
2-(2-aminoethyl)-1-methylpyrrolidine, 4-(aminomethyl)piperidine, 2-(aminomethyl)-1-ethylpyrrolidine, 4-pyrrolidinobutylamine,
1-(3-aminopropyl)pyrrolidine, 1-(3-aminopropyl)-4-methylpiperazine, N-(3?-aminopropyl)-2-pyrrolidinone, benzoic acid, 2-(aminomethyl)-,
6-aminocaproic acid, pentanoic acid, 5-amino-, cyclohexanecarboxylic acid, 4-(aminomethyl)-, (2s)-4-amino-2-hydroxy-butyric
acid, tyramine, phenol, 2-(aminomethyl)-, phenol, 4-(aminomethyl)-, 3-methoxytyramine, 2-fluoroethanamine, 3-aminopyrrolidine,
4-aminopiperidine, ethyl 4-amino-1-piperidinecarboxylate, ethanone, 2-amino-1-(4-morpholinyl)-, 3-aminopropane-1,2-diol, 3-aminopropionitrile,
3-amino-1-propanol, 2-(2-aminoethoxy)ethanol, 2-(1h-indol-3-yl)ethanamine (tryptamine), 3-(2-aminoethyl)pyridine, 1h-indole-2-methanamine,
acetamide, 2-amino-N-(1-methylethyl)-, 2-(2-methoxyphenyl)ethylamine, 2-(aminomethyl)pyridine, phenylalanine, 3,5-dimethyl-,
glutamic acid, butanoic acid, 2-amino-, d-phenylalanine, 3-fluoro-, benzeneacetic acid, ?-amino-4-fluoro-, tyrosine, 3-fluoro-,
4-pyridinepropanoic acid, ?-amino-, (a r)-, asparagine, beta alanine napthylamide, 1-leucine-4-nitroanilide, 2-amino-3-methyl-3-sulfanylbutanoic
acid, 1,2,3,4-tetrahydro-1-naphthylamine, 4-(2-aminoethyl)pyridine, 2-thiophenemethylamine, 4-(aminomethyl)pyridine, 3-(aminomethyl)pyridine,
3-bromo-4-methoxyphenethylamine, 3-furanmethanamine, 2-quinolinemethanamine, homopiperazine, propanamide, 3-amino-N-methyl-,
2-(2-furylmethylthio)ethanamine, 4-(2-aminoethyl)benzenesulfonamide, 5-aminomethyl-2-chloropyridine, (s)-(?)-1-(3-methoxyphenyl)ethylamine,
(s)-(?)-1-(4-methoxyphenyl)ethylamine, cis-2, 6 dimethylpiperazine, 3-pyrrolidinecarboxylic acid, 3-piperidinecarboxylic acid,
1h-imidazole, 1-(3-pyrrolidinyl)-, 5h-pyrrolo[3,4-b]pyridine, 6,7-dihydro-, pyridine, 2-(3-pyrrolidinyl)-, pyrrolidine, 3-(methyl
sulfonyl)-, 3-pyrrolidinecarboxamide, phenylalanine, 4-ethyl-, 5-methoxytryptamine, N-acetylethylenediamine, s-(2-aminoethyl)isothiouronium
bromide, homotaurine, (r)-1-(3-methoxyphenyl)ethylamine, 2-(3,4-dimethoxyphenyl)ethylamine, 3-methoxyphenethylamine, 2-(4-methoxyphenyl)ethylamine,
4-methoxybenzylamine, 2-phenoxyethylamine, 2-methoxybenzylamine, 3-methoxybenzylamine, phenylalanine, 4-ethyl-, benzeneacetic
acid, ?-amino-, glutamine, benzeneacetic acid, ?-amino-4-hydroxy-, (? r)-, butanoic acid, 2-amino-3-hydroxy-, 3-thiopheneacetic
acid, ?-amino-, benzoic acid, 2-amino-5-hydroxy-, 4-amino-1-butanol, and 4-dimethylaminobenzylamine, and

wherein the attachment point between the R1-R4 groups and the structure is through the N of the R1-R4 groups.

US Pat. No. 9,512,194

MODIFIED IL-13 POLYPEPTIDES

The Board of Trustees of ...

1. A modified IL-13 polypeptide engineered to have decreased affinity for interleukin 13 receptor ?2 (IL-13R?2), relative
to native human IL 13 protein; (b) and increased affinity for interleukin 13 receptor ?1 (IL-13R?1) relative to native human
IL 13 protein;
wherein the modified IL-13 polypeptide comprises amino acid changes relative to wild type IL-13 at positions V18, D87, T88,
L101, K104, and K105.

US Pat. No. 9,472,694

COMPOSITION AND METHOD FOR UPCONVERSION OF LIGHT AND DEVICES INCORPORATING SAME

The Board of Trustees of ...

16. An article comprising an up-converting electrode, wherein the up-converting electrode comprises a substantially uniform,
electrically conductive, single layer hybrid film consisting of:
a material that is capable of up-converting light having a wavelength greater than about 730 nanometers to light having a
wavelength that is less than 730 nanometers; and

metallic nanowires having a plasmonic resonance that overlaps at least one of an absorption or emission of the material that
is capable of up-converting light, wherein, when intermingled in the hybrid film with the material that is capable of up-converting
light, the metallic nanowires increases generation of upconverted photons by a factor of at least four, relative to using
the first material that is capable of up-converting light alone.

US Pat. No. 9,453,774

SURFACE AREA-BASED PRESSURE SENSING

The Board of Trustees of ...

1. An apparatus comprising:
an electrode; and
a plurality of structures having respective surface areas that contact at least one of the electrode and other ones of the
structures, the structures being configured and arranged with the electrode to provide an electrical indication of pressure
by

effecting a change in the respective surface areas relative to the electrode in response to an elastic compression or expansion
of the structures, and

providing a change in electrical impedance between the structures and the electrode that is based on the change in the respective
surface areas.

US Pat. No. 9,382,313

MODULATION OF SYNAPTIC MAINTENANCE

The Board of Trustees of ...

1. A method of treating a patient afflicted with a neurodegenerative disorder of the peripheral nervous system, the method
comprising administering to the patient a therapeutic amount of a complement inhibitor to thereby treat the neurodegenerative
disorder of the peripheral nervous system, wherein the complement inhibitor is an antibody that binds to a component of the
C1 complex, wherein the component of the C1 complex is selected from the group consisting of C1q, C1s and C1r.
US Pat. No. 9,329,170

SINGLE CELL GENE EXPRESSION FOR DIAGNOSIS, PROGNOSIS AND IDENTIFICATION OF DRUG TARGETS

The Board of Trustees of ...

1. A method of identifying different cell populations in a heterogeneous cell sample, comprising:
randomly partitioning individual cells from said heterogeneous cell sample into discrete locations on a cell capture array
with wells just large enough to fit a single cell;

identifying certain individually partitioned cells in the discrete locations on the cell capture array using one or more surface
markers;

sorting the certain individually partitioned cells from the discrete locations using a microfluidic device;
performing transcriptome analysis on a plurality of genes of the individually sorted cells from the discrete locations; and
performing clustering analysis to identify different cell populations.

US Pat. No. 9,331,737

SYSTEMS AND METHODS FOR CANCELLING INTERFERENCE USING MULTIPLE ATTENUATION DELAYS

The Board of Trustees of ...

1. A wireless communication device comprising:
at least one antenna for receiving or transmitting a signal;
a cancellation circuitry adapted to receive a first sample of a transmit signal, said cancellation circuitry comprising:
a control block;
a subtractor;
N paths, each path comprising a delay element and an associated variable attenuator whose attenuation level varies in response
to the control block, each path receiving the first sample of the transmit signal and generating a delayed and weighted version
of the first sample of the transmit signal; wherein a delay element disposed in a first one of the N paths generates a delay
shorter than a self-interference arrival time, and wherein a delay element disposed in a second one of the N paths generates
a delay longer than the self-interference arrival time; wherein the self-interference arrival time is a delay between arrival
of a second sample of a transmit signal at the cancellation circuitry and arrival of a corresponding self-interference signal
at the subtractor; wherein the corresponding self-interference signal comprises self-interference resulting from transmission
of the second sample of the transmit signal;

a combiner adapted to combine the N delayed and weighted versions of first sample of the transmit signal to construct a signal
representative of a first portion of a self-interference signal;

wherein the subtractor is adapted to subtract the constructed signal from a received signal, wherein N is an integer greater
than or equal to 2.

US Pat. No. 9,310,352

BIOLOGICAL CELL NANOCAVITY PROBES

The Board of Trustees of ...

1. Apparatus comprising:
an optical fiber having an exposed fiber surface;
a photonic crystal structure (PCS) affixed to the optical fiber and optically coupled to the optical fiber, wherein the PCS
is disposed on or in proximity to the exposed fiber surface;

wherein the PCS comprises an elongate probe member configured for biological probing; and
wherein the elongate probe member comprises an optical resonant cavity.

US Pat. No. 9,254,505

METHOD FOR MANUFACTURING NANOWIRE MESHES

The Board of Trustees of ...

1. A method comprising:
synthesizing nanowires containing silver in a solution containing a structure-directing agent;
forming a sheet of nanowires from the synthesizing nanowires; and
heating the sheet of nanowires at a temperature and for a time sufficient to remove the structure-directing agent and to produce
a sheet conductivity level, for the sheet of nanowires, that is less than 25 ohms per square and a sheet transmittance, for
the sheet of nanowires, of at least about 80% for all wavelengths between about 400 nanometers and 800 nanometers.

US Pat. No. 9,125,570

REAL-TIME TOMOSYNTHESIS GUIDANCE FOR RADIATION THERAPY

The Board of Trustees of ...

1. A method for delivering radiation therapy to a mammal comprising:
scanning an electron beam over an x-ray target to produce x-rays from a plurality of x-ray focal spots;
directing said x-rays towards an imaging field of view and a specified object in said imaging field of view in said mammal;
measuring amount of said x-rays striking a detector with an active imaging area smaller than an area of said imaging field
of view;

producing a first pixel representation of said object based on amount of said x-rays striking said detector from a first x-ray
focal spot of said plurality of x-ray focal spots;

producing a second pixel representation of said object based on amount of said x-rays striking said detector from a second
x-ray focal spot of said plurality of x-ray focal spots;

tracking movement of said object using said first pixel representation and said second pixel representation;
analyzing image quality of said object in each plane of a plurality of planes;
identifying a single plane of best focus of said object from said plurality of planes based on said analyzed image quality;
identifying position of said object along a direction corresponding to plane displacement based on said single plane of best
focus; and

controlling radiation from a radiation therapy source towards said object.
US Pat. No. 9,068,224

MEASUREMENT AND MONITORING OF CELL CLONALITY

THE BOARD OF TRUSTEES OF ...

1. A method of determining the clonal expansion of B cells in response of an individual to a vaccine, the method comprising:
obtaining a cell sample comprising B cells from said individual in a short defined time period following immunization with
said vaccine;

dividing said cell sample comprising B cells, or genomic DNA derived therefrom, into at least two distinct pools;
amplifying genomic DNA sequences at an immunoglobulin heavy chain locus in said at least two distinct pools with a primer
set that amplifies at least 50% of the known rearrangements at the locus;

sequencing at least 103 reads of the amplified genomic DNA at the locus of interest from said at least two distinct pools;

comparing sequences from said amplified genomic DNA to detect the presence of sequences that are coincident in said at least
two distinct pools of nucleic acid;

wherein the presence of coincident sequences is indicative of clonal expansion and responsiveness to said vaccine.

US Pat. No. 9,063,573

METHOD AND SYSTEM FOR TOUCH-FREE CONTROL OF DEVICES

The Board of Trustees of ...

1. A method for providing input to a device, comprising:
receiving multiple image information for a first predetermined space, wherein image information is received from a camera
positioned substantially near a display device, wherein the camera receives light from a direction substantially perpendicular
to the display device, and wherein the camera receives light from a light-bending apparatus positioned substantially near
the camera so as to bend light emanating from substantially near and in front of the display device;

displaying an image on the display device, wherein the image includes at least one predetermined area corresponding to at
least one predetermined input;

identifying at least one active part from the image information;
receiving depth cue information for the at least one active part;
identifying a three-dimensional gesture of the at least one active part;
generating action information for the at least one active part in the first predetermined space based on the identified three-dimensional
gesture when the at least one active part is determined to be substantially close to at least one of the at least one predetermined
areas, wherein the action information includes depth of field information for the at least one active part, and wherein the
action information includes at least one of the at least one predetermined input;

performing a predetermined computing action based on the generated action information.

US Pat. No. 9,507,064

DIELECTRIC METASURFACE OPTICAL ELEMENTS

The Board of Trustees of ...

1. A dielectric gradient metasurface optical device comprising a less than 100 nm thick layer of nanoscale geometric Pancharatnam-Berry
phase optical elements deposited on a substrate layer, wherein the optical elements are nanobeams composed of high refractive
index dielectric material, wherein the nanobeams have uniform size and shape and are arranged with less than 200 nm separations
and spatially varying orientations in the plane of the device such that the optical device has a spatially varying optical
phase response capable of optical wavefront shaping.